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ABSTRACT 
Rapidly emerging strains of bacteria resistant to most advanced antibiotics have become 
issues of very important public health concern. Research currently directed towards marine 
actinomycetes presents a vast potential for new compounds that could be able to safely and 
effectively target resistant species. In this regard, ten putative Streptomyces strains isolated from the 
Nahoon beach were selected and assessed for antibiotic production and activity against a wide range 
of bacteria including reference strains, environmental strain and clinical isolates. The ethyl acetate 
extracts of the putative Streptomyces isolates showed activities against at least 6 and up to 26 of the 
32 test bacteria. Inhibition zones were found to range between 9-32 mm diameters at a concentration 
of 10 mg/ml. The minimum inhibitory concentrations (MICs) of the crude extracts ranged from 
0.039 - 10 mg/ml and the least minimum bactericidal concentration (MBC) demonstrated was 0.625 
mg/ml against a reference strain Staphylococcus aureus ATCC 6538. Time kill kinetics of all 
extracts revealed bacteristatic and bactericidal activities. Average Log reductions in viable cell 
counts for all the extracts ranged from 0.86 Log10 and 3.99 Log10 cfu/ml after 3 h interaction and 0.01 
Log10 and 4.86 Log10 after 6 h interaction at MIC, 2 × MIC, 3 × MIC and 4 × MIC concentrations. 
Most of the extracts were speedily bactericidal at 3 × MIC and 4 × MIC resulting in over 50 % 
elimination of most of the test bacteria within 3 h and 6 h interaction. The partial characterization of 
the crude extracts by IR spectral analysis revealed possibility of terpenoid, long chain fatty acids and 
secondary amine derivatives compounds in the extracts. It is therefore recommended that further 
investigation should address the relationship between the structure of the active component of the 
extracts and the broad spectrum activity, as well as a rapid method for large scale production and 
purification and whether this group of antibiotics has any application in managing human infectious 
disease. 
1 
 
CHAPTER ONE 
 
1.0            Background of study 
A few decades after the introduction of antibiotics into clinical practice, resistance by pathogenic 
bacteria has become a major health concern. Indeed, while in the mid 1970s infectious diseases were 
considered virtually conquered (Breithaupt, 1999); many Gram positive bacteria and Gram negative 
opportunistic pathogens were becoming resistant to virtually every clinically available drug 
(Greenberg, 2003). The use of antimicrobial drugs for prophylactic or therapeutic purposes in human 
and veterinary or for agricultural purposes, have provided the selective pressure favouring the 
survival and spread of resistant organisms. Staphylococcus aureus, for instance, a virulent pathogen 
that is responsible for a wide range of infections including pimples, pneumonia, osteomyelitis, 
endocarditis and bacteremia, has developed resistance to most classes of antibiotics.  
 Methicillin-resistant S. aureus (MRSA) strains appeared in the hospital environment after 
introduction of the semi-synthetic penicillin and methicillin, leaving vancomycin as the last chance 
for MRSA treatment (Enright, 2003). Vancomycin is the last tool for the treatment of the infections 
caused by the resistant Gram positive microorganisms including MRSA (Enright, 2003). Indeed, 
vancomycin resistance is difficult to acquire because it is a complex system involving up to 7 genes. 
However vancomycin-intermediately-sensitive S. aureus were first isolated in 1997 in Japan and 
later in other countries (Fridkin, 2001). In fact, vancomycin-resistant clinical isolates have been 
recently reported (Tenover et al., 2004). Thus currently, no antibiotic class is effective against multi-
resistant S. aureus infections and new antibiotics or alternative chemotherapeutic strategies are 
urgently needed. 
 Enterococci are responsible for urinary tract, wound, intra abdominal, and pelvic infections 
(Barsby et al., 2001). The increase of vancomycin-resistant enterococci (VRE) as important agents of 
nosocomial infections is cause for great concern (Perl, 1999). It is thought that a selective pressure 
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favouring the survival and spread of VRE was the consequence of the use of antibiotics in food and 
agricultural practices (Bax, 2000). Actually, there are no effective antibiotics currently available for 
such organisms. Even worse, vancomycin-resistance is often associated with multiple-drug resistance 
(Perl, 1999). 
 Another cause of great concern is the Gram-negative antibiotic-resistant opportunistic 
pathogens. These bacteria, like Pseudomonas aeruginosa, are common environmental organisms, 
which act as opportunistic pathogens in clinical cases where the defense system for patient is 
compromised (Lyczak et al., 2000). For instance, over 80 % of cystic fibrosis (CF) patients become 
chronically infected with P. aeruginosa (Lyczak et al., 2000). In addition, other intrinsically 
antibiotic resistant organisms such as Burkholderia cepacia and Stenotrophomonas maltophilia 
(Saiman et al., 2002), are emerging as opportunistic pathogens. Interestingly, changes in the bacterial 
phenotype have been observed concomitant with the appearance or increase of antibiotic resistance. 
Indeed, in CF infections, initially, strains are non mucoid, but over time a mucoid population 
showing slow growth phenotype with an increased capability to form biofilms, the small colony 
variants (SCV), develops (Haussler et al., 1999). This ability is considered a major virulence trait 
because the bacteria are protected from adverse environmental conditions as well as from biological 
and chemical antibacterial agents (Haussler, 2004). Thus, new therapeutic drugs and/or approaches 
are needed to improve the management of these diseases and overcome these problems (Taylor et al., 
2002). 
 The appearance of multi resistant pathogenic strains has caused a therapeutic problem of 
enormous proportions. For instance, they cause substantial morbidity and mortality especially among 
the elderly and immunocompromised patients. In response, there is a renewed interest in discovering 
novel classes of antibiotics that have different mechanisms of action (Barsby et al., 2001). With 
increasing misuses of antibiotics, the serious problems of antibiotic resistance are developing at an 
alarming rate. Hence, intensive search for new antibiotics has become imperative worldwide (Haque 
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et al., 1995; Oskay et al., 2004; Parungao et al., 2007) especially from new actinomycetes such as 
Streptomyces which is known as the greatest source of antibiotics. 
 The screening of microbial natural products continues to represent an important route to the 
discovery of novel chemicals, for development of new therapeutic agents and for evaluation of the 
potential of lesser-known and/or new bacterial taxa (Lazzarini et al., 2000). It has been estimated that 
approximately two-third of the thousands of naturally occurring antibiotics have been isolated from 
actinomycetes (Takizawa et al., 1993). Indeed, the Streptomyces species produce about 75% of 
commercially and medically useful antibiotics (Miyadoh, 1993). 
 New microbial metabolites are permanently needed due not only to the increase in resistant 
pathogens, but also to the evolution of novel diseases and toxicity of currently used compounds 
(Demain, 1999). Therefore, several strategies have to be employed to find new bioactive drugs 
including the exploration for new compounds from well known and talented microorganisms, such as 
Streptomycetes, due to the fact that only a small range of their biosynthetic capacity is currently 
exploited (Zahner et al., 1995). 
   
1.1 Aim and Objectives of the study 
This study aims at exploring the antibiotics production potentials of some indigenous marine 
Streptomyces isolated from the Nahoon beach in the Eastern Cape Province of South Africa. The 
specific objectives include: 
1. To prepare crude ethyl acetate extracts of the Streptomyces fermentation products. 
2. To screen the crude extracts for antibacterial activities using a panel of bacterial strains.  
3. To determine the minimum inhibitory concentration (MIC) and minimum bactericidal 
concentration (MBC) of the extracts. 
4. To determine rate of kill of the crude ethyl acetate extracts on selected susceptible bacteria. 
5. To characterize the ethyl acetate crude extracts of the Streptomyces fermentation products. 
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1.2 The rationale for the study (Justification) 
The screening of microbial natural products continues to represent an important route to the 
discovery of novel chemicals for the development of new therapeutic agents, and evaluation of the 
potential of lesser-known and/or new bacterial taxa (Bull et al., 2000). There has been considerable 
progress on the detection and identification of marine microorganisms since they were reported to 
produce novel bioactive compounds (Fenical, 1993; Copp, 2003; Shin et al., 2003). It is necessary to 
continue to screen for new metabolites and evaluate the potential of less known and new bacterial 
taxa so that new and improved compounds for future use against drug-resistant bacteria or for 
chemical modification purposes may be developed (Kurtboke, 2005). 
 One of the efficient ways of discovering novel bioactive metabolites is through isolating new 
microorganisms, especially actinomycetes which produce about 70% of the known bioactive 
metabolites (Miyadoh, 1993). Therefore, investigation of new ecosystems for isolation of 
actinomycetes is crucial for the discovery of novel actinomycetes and subsequently for natural 
product-based drug discovery. Recently, several studies reported the investigation of different 
habitats for isolation of novel actinomycetes as rich sources of bioactive compounds (Hozzein et al., 
2008). Watve et al. (2001), has estimated that only a fraction of the antibiotics produced by 
Streptomyces strains have been discovered, thus underestimating the actual potentials of this genus as 
sources of novel antibiotics.  
 Programmes aimed at the discovery of antibiotics and other bioactive metabolites from 
microbial sources have yielded an impressive number of compounds over the past 50 years, many of 
which have found applications in human medicine and agriculture. However, it soon became 
apparent during screening programmes that some microbial metabolites were discovered more 
frequently than others. As the number of described microbial metabolites increased, so did the 
probability of rediscovering known compounds (Busti et al., 2006). Also to thwart resistance of 
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microorganism to already available antibiotics, there is need for episodic swap of existing antibiotics.  
To combat these needs there is a call to screen underexplored habitat.  
 The Eastern Cape Province of South Africa is richly endowed with indigenous aquatic 
actinomycetes of which Streptomyces are most abundant (Ogunmwonyi, 2008), and there is no 
evidence in literature that suggests that these indigenous actinomycetes of the aquatic environment of 
the Eastern Cape Province have been explored for their antibiotics production potentials. Yet, the 
sustainable exploitation of Streptomyces for antibiotic production holds considerable promise as a 
strategy to combat infectious diseases. It is interesting that Streptomyces strains continue to provide a 
larger number and wider variety of new antibiotics than any other actinomycete genus, suggesting 
that substantial numbers of Streptomyces species or strains with novel antibiotic productivity exist in 
nature (Okami and Hotta, 1988; Hwang et al., 2001). Hence, I hypothesize that the marine 
Streptomyces diversity of Nahoon beach; a marine environment of the Eastern Cape Province of 
South Africa could be a potential source of novel antibacterial compounds. Extraction of these 
compounds, quantitative and qualitative screening of the bioactive compounds would lead to 
discovery of novel compound that can fight against organism pathogenic to humans. The discovery 
of this novel compound(s) would be useful to the pharmaceutical industry and medicine to compact 
prevailing human pathogens in South Africa and in the world at large. 
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CHAPTER TWO 
 
Literature Review 
 
2.0  Genus Streptomyces 
The genus Streptomyces was proposed by Waksman and Henrici in (1943). They are well known as a 
rich source of antibiotics and bioactive molecules and are thus considered to be a rich 
biotechnological resource. The genus Streptomyces belong to the family Streptomycetaceae, Order 
Actinomycetales, Phylum Actinobacteria, Domain Bacteria, and includes the following species: S. 
achromogenes, S. ambofaciens, S. aureofaciens, S. avermitilis, S. clavuligerus, S. coelicolor, S. 
felleus, S. ferralitis, S. filamentosus, S. griseus , S. hygroscopicus, S. iysosuperficus, S. lividans, S. 
noursei, S. scabies, S. somaliensis, S. thermoviolaceus, S. toxytricini, S. tsukubaensis, S. venezuelae, 
S. violaceoruber plus ~500 additional species (Kampfer, 2006). Streptomyces species are well known 
by a linear chromosome, complex morphological differentiation, and an ability to produce many 
bioactive secondary metabolites, containing important compounds for pharmaceutical and 
agrochemical uses (Arakawa et al., 2005; El-Gendy et al., 2008b). 
 
2.1 Marine Environments 
Marine ecosystems contain several unique features that set them apart from other aquatic 
ecosystems, the main factor being the presence of dissolved compounds in seawater, particularly 
sodium chloride (NaCl). Salinity is expressed as the amount (in grams) of total dissolved salts 
present in 1 kg of water. Normal seawater with a salinity of 35 g/kg (or litre) of water is expressed as 
35‰. Microorganisms, particularly fungi and yeasts are well known for their ability to grow in saline 
environments by adapting their osmoregulatory mechanisms that signal the production of osmolytes 
(e.g., polyols, amino acids) in conjunction with an increasing concentration of cytoplasmic ions 
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(Harris, 1981; Bloomberg and Adler, 1992; Roberts, 2005). For marine microorganisms, their 
cellular adaptation to moderate and high salt content is a fundamental biological process needed for 
survival and growth. It is postulated that marine microorganisms have different characteristics from 
those of their errestrial counterparts and, therefore, might produce different types of bioactive 
compounds (Mahyudin, 2008). 
 The definition of true marine Streptomyces is difficult but the ability of Streptomyces to grow 
in a marine environment has been demonstrated, notably in connection with their occurrence in salt-
rich muds and sea areas close to the shore. Earlier studies showed that Streptomyces spp. can grow at 
2 and 16% NaCl, while various species of Streptomyces and Nocardia grow well in the presence of 
10% NaCl (Mahyudin, 2008). More recently, other studies have shown that various actinomycetes 
derived from marine sediments show good growth in the presence of NaCl (Jensen et al., 1991; 
Mincer et al., 2002; Kokare et al., 2004; Magarvey et al., 2004; Mahyudin, 2008). 
 During the past 30 years, a large number of new compounds with structures completely 
different from those isolated from terrestrial organisms were successfully discovered from marine 
sources (Elyakov et al., 1994; El-Gendy et al., 2008b). Marine environment is a relatively untapped 
ecosystem with regards to isolation of indigenous Streptomyces, although existence of cousins of 
terrestrial origin has been reported (Solanki et al., 2008). The immense diversity of this habitat along 
with it’s under exploitation is the fundamental reason for attracting researchers towards it for 
discovering novel metabolite producers.  
 Interest in the importance of marine organisms as a source of new substances is growing. 
With marine species comprising approximately half of the total global biodiversity, the sea offers an 
enormous resource for novel compounds (de Vries and Beart, 1995), and it has been classified as the 
largest remaining reservoir of natural molecules to be evaluated for drug activity (Gerwick and 
Bernart, 1993). Marine and estuarine aquatic angiosperms, or sea grasses, produce antimicrobial 
compounds that may act to reduce or control microbial growth. Workers have described antibacterial 
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(Harrison and Chan, 1980; Bernard and Pesando, 1989; Devi et al., 1997; Bhosale et al., 2002), 
antialgal (Harrison, 1982), antifungal (Jensen et al., 1998) and antiviral (Premnathan et al., 1992) 
activities among marine organisms (Kumar et al., 2008). 
 Searching for previously unknown microbial strains is an effective approach for obtaining 
new biologically active substances. It is known that the antimicrobial activity of the metabolic 
products of aquatic bacterial strains is not weaker than the corresponding activity of soil strains. 
Water, bottom sediments, as well as sponges and other aquatic organisms are potential sources of 
producers of these metabolites (Sponga et al., 1999; Webster et al., 2001; Terkina et al., 2006). Over 
one half of the marine bacteria studied display antagonistic activity towards other pelagic bacteria 
(Long and Azam, 2001). Unilateral or bilateral antagonism, resulting from the effect of antibiotic 
substances, inhibits the growth of microorganisms or kills them. Antimicrobial interactions 
influence, first, the structure of the microbial community, i.e., the composition and diversity of 
bacterial species; second, the functioning of microbial cenoses; and overall, the nature and 
transformation rate of biogeochemical substances in water bodies (Long and Azam, 2001; Terkina et 
al., 2006). Actinomycetes are the strongest antagonists among microorganisms. The antibiotic 
substances they produce display antibacterial, antifungal, antitumor, antiprotozoic, and antiviral 
properties. Of the ten thousand known antibiotics produced by microorganisms over a decade ago, 
about 70% are of actinomycete origin; of them, representatives of the genus Streptomyces account 
for two thirds (Miyadoh, 1993). Actinomycetes from the genus Micromonospora occupy the second 
place in this list: they produce over 300 broad-spectrum antibiotic substances (Vobis, 1992). 
Representatives of the genera Micromonospora and Streptomyces are widely abundant in aquatic 
ecosystems and frequently prevail over other groups of actinomycetes (Sponga et al., 1999; Mincer 
et al., 2002; Terkina et al., 2006). 
 Within marine environments, taxonomically diverse bacterial groups exhibit unique 
physiological and structural characteristics that enable them to survive in extremes of pressure, 
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salinity and temperature, with the potential production of novel secondary metabolites not observed 
in terrestrial microorganisms (Cross, 1981; Gause et al., 1981; Radajewski et al., 2002). Much 
interest on the screening of marine and aquatic microorganisms is focused on screening sediment 
derived microorganisms (Bredholt et al., 2008; Jensen et al., 1991; Okazaki, 2003), and also on those 
that form highly specific symbiotic associations with marine plants and animals in response to the 
scarcity of nutrients in aquatic and marine environments, and thus produce compounds for defence 
and competition (Kurtböke, 2000; Eccleston et al., 2008). 
 
2.2  Secondary metabolites and their functions 
Secondary metabolites, also known as natural products, are those products of metabolism that are not 
essential for normal growth, development or reproduction of an organism. In this sense they are 
"secondary". Contrary to primary metabolites these compounds are not ubiquitous in the living 
organisms that produce them; neither are they necessarily expressed continuously (Demain and Fang, 
2000). Also, unlike primary metabolites, absence of secondary metabolites does not result in 
immediate death, but rather in long-term impairment of the organism's survivability, fecundity, or 
aesthetics, or perhaps in no significant change at all (Demain, 1992). Secondary metabolites are often 
restricted to a narrow set of species within a phylogenetic group.  They can be classified by their 
chemical structure or physical properties into one or more of the following groups: alkaloids, 
terpenoids, polyketides, aliphatic, aromatic, and heteroaromatic organic acids, phenols, iridoids , 
steroids, saponins, peptides, ethereal oils, resins and balsams (Demain and Fang, 2000). 
 Microbial secondary metabolites are the low molecular mass products of secondary 
metabolism. They include antibiotics, pigments, toxins, effectors of ecological competition and 
symbiosis, pheromones, enzyme inhibitors, immuno-modulating agents, receptor antagonists and 
agonists, pesticides, antitumour agents and growth promoters of animals and plants. They have a 
major effect on the health, nutrition and economics of our society (Demain, 1992).   
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The function or importance of these compounds to the organism's development is usually of 
ecological nature as they are used as defence against predators (herbivores, pathogens etc.), for 
interspecies competition, and to facilitate the reproductive processes (Demain and Fang, 2000). 
Secondary metabolites, including antibiotics, are produced in nature and serve survival functions for 
the organisms producing them. The antibiotics are a heterogeneous group, the functions of some 
being related to and others being unrelated to their antimicrobial activities. Secondary metabolites 
serve: (i) as competitive weapons used against other bacteria, fungi, amoebae, plants, insects, and 
large animals; (ii) as metal transporting agents; (iii) as agents of symbiosis between microbes and 
plants, nematodes, insects, and higher animals; (iv) as sexual hormones; and (v) as differentiation 
effectors (Demain and Fang, 2000). 
 Programmes aimed at the discovery of antibiotics and other bioactive metabolites from 
microbial sources have yielded an impressive number of compounds over the past 50 years, many of 
which have found applications in human medicine and agriculture. However, it soon became 
apparent during screening programmes that some microbial metabolites were discovered more 
frequently than others. As the number of described microbial metabolites increased, so did the 
probability of rediscovering known compounds. At the present time, with several thousands of 
described microbial metabolites, approach must be introduced into screening programmes to increase 
the chances of discovering novel compounds (Bull et al., 2000; Lancini et al., 1995, Busti et al., 
2006). 
 Secondary metabolites produced from marine actinomycetes have distinct chemical 
structures, which may form the basis for the synthesis of new drugs (Solanki et al., 2008). Selective 
and enrichment media is capable of isolating Streptomyces from marine natural environment having 
the possibility to produce novel bioactive compounds. In order to provide a reasonable chance of 
yielding novel antibiotics, strains belonging to novel taxa must: (1) be able to produce secondary 
metabolites; (2) possess diversified pathways for secondary metabolism; (3) present significant 
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genetic diversity; (4) be retrievable in large numbers; and (5) be amenable to scale-up for large-
volume fermentation (Busti et al., 2006). 
 
2.3 Genes for secondary metabolism 
Genes encoding enzymes responsible for the synthesis of secondary metabolites are usually clustered 
on a contiguous piece of DNA (Solanki et al., 2008). Genomic studies indicate that the genetic 
potential for producing secondary metabolites is not uniformly distributed within the bacterial world. 
In fact, most bacterial genomes lack any detectable gene cluster for secondary metabolism (Solanki 
et al., 2008). On the other hand, Streptomyces coelicolor (Bentley et al., 2002; Busti et al., 2006) and 
Streptomyces avermitilis (Ikeda et al., 2003; Omura et al., 2001; Busti et al., 2006), each possess 
more than 20 gene clusters devoted to the synthesis of secondary metabolites. Multiple gene clusters 
for secondary metabolism appear also to be a hallmark of several non-Streptomyces filamentous 
actinomycetes (Sosio et al., 2000; Busti et al., 2006) and of the myxobacteria (Gerth et al., 2003; 
Busti et al., 2005). It is interesting to point out that genomic data parallel the observed discovery 
events and indicate that Streptomycetes, Pseudomonads and Bacilli have yielded large numbers of 
metabolites since they can be easily isolated and have a relatively large genetic potential for 
producing secondary metabolites (Busti et al., 2006). It is thus likely that most microbial strains that 
could be isolated in large numbers have actually been screened for bioactivities (Busti et al., 2006). 
 A substantial fraction of the metabolites produced by Streptomyces and related actinomycetes 
consist of a polyketide or a polypeptide scaffold. Most peptide-derived metabolites are synthesized 
by NRPSs (Marahiel, 1997; Busti et al., 2006), while two major routes exist for polyketide synthesis 
in actinomycetes (Hopwood, 1997; Busti et al., 2006); one employs type I enzymes (PKS-I), also 
known as modular PKSs; and the other uses type II systems (PKS-II), mostly responsible for the 
synthesis of aromatic polyketides. Typical of actinomycetes is the presence, in a single strain, of 
genes encoding PKS-I, PKS-II and NRPSs. PKS-I and NRPS genes present a modular organization, 
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with a repetition of similar gene segments within a single gene cluster, so each amplified band may 
consist of different sequences originating from a single cluster (Busti et al., 2006). In addition, a 
single actinomycetes strain normally contains more than one PKS-I or NRPS cluster. However, since 
KS and A domains present considerable sequence variation, primer pairs are seldom universal and 
can amplify only a fraction of the genes present. Consequently, only a fraction of the entire PKS-I or 
NRPS modules can be accessed through PCR (Busti et al., 2006). 
 
2.4 Marine Streptomyces producing secondary metabolite 
Marine Streptomyces have proven to be efficient producers of new secondary metabolites  (Solanki 
et al., 2008), which show a range of biological activities such as antifungal, antitumor, antibacterial, 
immunosuppressive, insecticidal and enzyme inhibition, to name a few. 
Secondary metabolites produced by marine Streptomycetes can be classified on the basis of their 
chemical structure as follows: 
 
2.4.1 Terpenes and terpenoids 
The most chemically diverse pool of secondary metabolites in nature is constituted by terpenes 
(Wendt and Schulz, 1998). In 1956, novobiocin was isolated as the first antibiotic with a terpenoid 
side chain from Streptomyces niveus (Hoeksema and Smith, 1961). Terpenes have been reported 
from the marine Streptomyces as evidenced by the following compounds: 
a. Azamerone a meroterpenoid produced by a new marine bacterium related to the genus 
Streptomyces (Cho et al., 2006a). It appears to be the first natural product with a phthalazione 
ring. 
b. Three new pyrrolosesquiterpenes, glaciapyrroles A, B and C are produced by a Streptomyces 
strain (NPSOO 8187); and showed antibacterial activities (Macherla et al., 2005). 
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c. Amorphane sesquiterpenes namely 10 α, 15-dihydroxyamorph-4-en-3-one, 10α, 11-dihydr-
oxyamorph-4-ene and 5α,10 α,11-trihydroxyamorphan-3-one were produced by Streptomyces 
sp. M491 (Wu et al., 2007). This is the first report of these sesquiterpenes from bacteria. 
 
2.4.2 Polyketides 
A marine inhabitant known as Streptomyces psommoticus produced antibiotic SBR-22 (Sujatha et 
al., 2005) which showed antibacterial activity against methicillin-resistant Staphylococcus aureus. 
a. Daryamides are cytotoxic polyketides isolated from culture broth of a Streptomyces strain, 
CNQ-085. These bioactive compounds show weak to moderate cytotoxicity against the 
human colon carcinoma cell line HCT-116 and very weak antifungal activities against 
Candida albicans (Asolkar et al., 2006). 
b. Actinofuranones A and B were isolated from the fermentation broth of a marine bacterium 
related to Streptomyces genus and show weak in vitro cytotoxicity against mouse splenocyte 
T-cells and macrophages (Cho et al., 2006b). 
 
2.4.3 Peptides 
a. Cyclomarins A-C is cyclic peptides produced by a Streptomyces sp. that showed anti-
inflammatory and antiviral activities (Renner et al., 1999). 
b. Piperazimycins are cytotoxic hexadepsipeptides isolated from the fermentation broth of a 
Streptomyces sp. Piperazimycin A exhibits potent invitro cytotoxicity against multiple tumor 
cell lines (Miller et al., 2007). 
c. Two cyclic peptides dehydroxynocardamine and desmethylenylnocardamine (Lee et al., 
2005); along with nocardamine was isolated from a Streptomyces sp. which was obtained 
from an unidentified marine sponge. These new compounds exhibit weak inhibition against 
the enzyme sortase B (Lee et al., 2005). 
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d. Salinamides A and B are bicyclic depsipeptides produced by a Streptomyces sp., CNB-091, 
isolated from jelly fish Cassiopeia xamachana. These metabolites are useful as antibiotic and 
anti-inflammatory agents (Moore et al., 1999). 
 
2.4.4 Caprolactones 
Two new caprolactones R-10-methyl-6-undecanolide and (6R, 10S)-10-methyl-6-dodeconolide are 
produced by a marine Streptomyces sp. These caprolactones show a moderate phytotoxicity and low 
cytotoxicity against cancer cells (Stritzke et al., 2004). 
 
2.4.5 Piericidins 
Piericidins C7 and C8 produced by marine Streptomyces sp. showed selective cytotoxicity against rat 
glia cells transformed with the adenovirus EIA gene and neuro-2a mouse neuroblastoma cells 
(Hayakawa et al., 2007).  
 
2.4.6 Quinones 
a. Resistomycin an antibiotic related to quinones, is produced by Streptomyces corchorusii. 
This is an inhibitor of HIV-1 protease (Shiono et al., 2002). 
b. Tetracenomycin D is an anthraquinone antibiotic produced by Streptomyces corchorusii. It 
shows cytotoxicity against cell line HMO2 (gastric adenocarcinoma) and HepG2 (hepatic 
carcinoma) and possesses weak antibacterial activities against gram-positive and gram-
negative bacteria (Adinaryan et al., 2006). 
c. Resistoflavine is produced by Streptomyces chibaensis. It shows cytotoxicity against cell line 
HMO2 (gastric adenocarcinoma) and HepG2 (hepatic carcinoma) and possesses weak 
antibacterial activities against gram-positive and gram-negative bacteria (Kock et al., 2005; 
Gorajana et al., 2007). 
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d. Komodoquinone A is a neuritogenic anthracycline isolated from the fermentation broth of a 
marine Streptomyces sp. K53. It induces cell differentiation in the neuroblastoma cell line, 
Neuro2A and arrests cell cycle at the G1 phase (Itoh, 2003). 
e. Himalomycins A and B are two new quinone antibiotics from a Streptomyces isolate, B6921. 
Himalomycins exhibit strong antibacterial activity against Bacillus subtilis, Streptomyces 
viridochromogenes, Staphylococcus aureus and Escherichia coli (Maskey et al., 2003). 
f. Helquinolines are new tetrahydroquinoline antibiotic isolated from culture broth of 
Janibacter limosus. Helquinoline shows moderate activity against Bacillus subtilis, 
Streptomyces virdochromogenes Tu57 and Staphylococcus aureus (Asolkar et al., 2004). 
g. CNQ-525 is a member of a new genus (tentatively called MAR4) within the family 
Streptomycetaceae, which produces three novel chlorinated dihydroquinones. These 
compounds possess new carbon skeletons but are related to several previously reported 
metabolites of the napyradiomycin class. The metabolites possess significant antibiotic 
properties and cytotoxicity against cancer cells (Mercado et al., 2005). 
 
2.4.7 Macrolides 
A marine Streptomyces sp. M491 has been reported to produce a macrolide antibiotic named 
Chalcomycin A and also some terpenes (Wu et al., 2007). 
 
2.4.8 Esters 
Bonactin is an antimicrobial ester produced by Streptomyces sp. BD21-2. Bonactin displayed 
antimicrobial activity against gram-positive and gram-negative bacteria as well as against several 
fungi (Schumacher et al., 2003). 
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2.4.9 Chinikomycins  
Chinikomycins A and B are chlorine containing aromatic manumycin derivatives. They exhibit 
antitumor activity against different human cancer cell lines, but are inactive as antiviral, 
antimicrobial and phytotoxic agents. These compounds are produced by Streptomyces sp. isolate 
MO45 (Li et al., 2005). 
 
2.4.10 Trioxacarcins 
Trioxacarcins are complex compounds showing high antibacterial activity against gram-positive and 
gram-negative bacteria, and some of them show high antitumor and antimalarial activities as well. 
Trioxacarcin A also exhibits antifungal activities. Trioxacarcin A, B and C are obtained from 
Streptomyces ochraceus and Streptomyces bottropensis (Maskey et al., 2004). Some of these 
compounds possess extremely high antiplasmodial activity, which is comparable to that shown by 
artemisinin, the most active compound against the pathogen of malaria (Maskey et al., 2004). The 
producers of trioxacarcins also biosynthesize the related metabolite, gutingimycin (Maskey et al., 
2004). 
 
2.4.11 Methyl pyridine 
Streptokordin a new cytotoxic compound of the methylpyridine class was isolated from the cultural 
broth of Streptomyces sp. KORDI-3238. It exhibits significant cytotoxicity against several human 
cancer cell lines but showed no growth inhibition against various microorganisms, including bacteria 
and fungi (Jeong et al., 2006). 
 
2.4.12 Lactams 
Aureoverticillactam, a novel 22-atom macrocyclic lactam was isolated from Streptomyces 
aureoverticillaris. It showed cytotoxicity against various tumor cell lines (Mitchell et al., 2004). 
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Salinosporamide A and aureoverticillactam are lactams from marine actinomycetes. These are 
distinct from β-lactam compounds which contain a four-membered β-lactam ring. The structure of β-
lactam second ring allows these compounds to be classified into penicillins, cephalosporins, clavams, 
carbapenes and monobactans (Liras and Martin, 2006). Most β-lactam compounds inhibit bacterial 
cell wall synthesis but others behave as β-lactamase inhibitors (e.g. cluvalanic acid) and even as 
antifungal agents (e.g. some clavams) (Liras and Martin, 2006), however salinosporamide A and 
aureoverticillactam showed cytotoxicity against cancer cells (Liras and Martin, 2006). 
 
2.4.13 Enzyme inhibitors 
Some enzymes inhibitors have been reported from marine environment and they include: 
a. Alpha amylase inhibitor from Streptomyces corchorusii subsp. rhodomarinus. Subsp. nov 
(Imada and Simidu, 1988). 
b. Pyrostatins A and B inhibitors of n-acetyl-beta-glucosaminidase, produced by Streptomyces 
sp. SA-3501 (Aoyama et al., 2005). 
c. Pyrizinostatin is an inhibitor of pyroglutamyl peptidase, isolated from culture of Streptomyces 
sp. SA-2289 (Aoyagi et al., 1992; Solanki et al., 2008). 
 
2.5 Antibiotics  
The first antibiotics were of natural origin, e.g. penicillins produced by fungi in the genus 
Penicillium, or Streptomycin from bacteria of the genus Streptomyces. Currently, antibiotics are 
obtained by chemical synthesis, such as the sulfa drugs (e.g. sulfamethoxazole), or by chemical 
modification of compounds of natural origin. Many antibiotics are relatively small molecules with a 
molecular weight of less than 1000 Da. The classical definition of an antibiotic is a compound 
produced by a microorganism which inhibits the growth of another microorganism (Mayer et al., 
1986). Antibiotics can be grouped by either their chemical structure or mechanism of action 
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(Kümmerer, 2009). They are a diverse group of chemicals that can be divided into different sub-
groups such as β-lactams, quinolones, tetracyclines, macrolides, sulphonamides and others is shown 
in Table 2.1. They are often complex molecules which may possess different functionalities within 
the same molecule. Therefore, under different pH conditions antibiotics can be neutral, cationic, 
anionic, or zwitterionic. Because of the different functionalities within a single molecule, their 
physico-chemical and biological properties such as log Pow (Cunningham, 2008; Kümmerer, 2009) 
sorption behaviour, photo reactivity and antibiotic activity and toxicity may change with pH 
(Kümmerer, 2009). 
 Antibiotics are a chemically diverse group of compounds produced by microorganisms that 
have microstatic or microcidal activity. They function by a variety of mechanisms to disrupt 
microbial metabolism. The discovery and clinical use of antibiotics just over 50 years ago coupled 
with improvements in immunizations drastically reduced human suffering and deaths from infectious 
diseases (Nwosu, 2001). In addition to antibiotics, many semi-synthetic derivatives of antibiotics and 
synthetic antimicrobial agents are used in clinics and animal husbandry. What is now apparent from 
the medical and nonmedical use and abuse of antibiotics is a growing body of evidence of antibiotic 
resistance in microorganisms. Evidence of resistance came soon after clinical use of antibiotics and 
has been accelerating so rapidly that the threat of resurgence of infectious diseases as a major human 
threat is real (Nwosu, 2001). 
 Antimicrobial drugs have generally been classified into two categories; one includes the 
synthetic drugs, such as the sulfonamides and the quinolones, and the second, antibiotics, 
synthesized by microorganisms. In recent years, increasing numbers of semi-synthetic drugs have 
been developed which are chemical derivatives of antibiotics, thereby blurring the distinction 
between synthetic and natural antibiotics (Gangle, 2005). 
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Table 2.1: Summary of bioactive compounds produced by marine Streptomyces 
 
Chemical group  Compound  Source  Activity 
Meroterpenoid Azamerone  Streptomyces sp. None 
Pyrrolosesquiterpenes Glaciapyrroles A, B and C  Streptomyces sp. 
NPS008187 
 
Antibacterial 
 
Amorphane 
sesquiterpenes 
 
10α, 15-dihydroxyamorph-4-
en-3-one, 
10α, 11-dihydroxyamorph-4-
ene and 
5α, 10α, 11-
trihydroxyamorphan-3-one 
 
Streptomyces sp. M491 None 
 
Polyketide SBR-22  Steptomyces psommoticus 
BT408 
 
Antibacterial 
 
Polyketide Daryamides  Streptomyces sp.CNQ-085 Anticancer, 
antifungal 
Polyketide Actinofuranones A and B  Streptomyces sp. Cytotoxic 
Peptide Piperazimycins  Streptomyces sp. Anticancer 
Peptide Dehydroxynocardamine and 
desmethylenylnocardamine  
Streptomyces sp. Enzyme sortase B 
inhibitor 
 
Peptide Salinamides A and B  Streptomyces sp. Antibacterial, 
anti-infl 
ammatory 
 
 Caprolactone R-10-methyl-6-undecanolide 
(6R,10S)- 
10-methyl-6-dodeconolide  
Streptomyces sp. B6007 Phytotoxic, 
anticancer 
Piericidin Piericidins C7 and C8  Streptomyces Anticancer 
Quinone Resistomycin  Streptomyces corchorusii 
AUBN(1)/7 
 
Antiviral 
 
Quinone Tetracenomycin D  Streptomyces corchorusii 
AUBN(1)/7 
 
Anticancer, 
antibacterial 
 
Quinone Resistoflavine  Streptomyces chibaensis 
AUBN(1)/7 
 
Anticancer, 
antibacterial 
 
Quinone Komodoquinone A  Streptomyces sp. K53 Neuritogenic 
activity 
Quinone Himalomycins A and B  Streptomyces sp. B6921 Antibacterial 
 
Macrolide Chalcomycin A  Streptomyces sp. M491 None 
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Manumycin 
derivatives 
Chinikomycins A and B  Streptomyces sp. M045 Anticancer 
 
Complex compounds Trioxacarcins  Streptomyces ochraceus 
and Streptomyces 
bottropensis 
 
Anticancer, 
antimalarial 
Methylpyridine Streptokordin  Streptomyces sp. 
KORDI-3238 
 
Anticancer 
 
Gamma lactam beta 
lactone 
 
Salinosporamide A  Salinispora tropica Anticancer 
Macrocyclic lactam Aureoverticillactam  Streptomyces 
aureoverticillaris 
 
Anticancer 
 
Enzyme inhibitor Alpha-amylase inhibitor  Streptomyces 
corchorusii subsp. 
rhodomarinus subsp. nov 
 
Enzyme 
Inhibition nov 
 
Enzyme inhibitor Pyrostatins A and B  Streptomyces sp. SA-3501 N-acetyl-
betaglucosaminid
ase 
inhibition 
 
Enzyme inhibitor Pyrizinostatin  Streptomyces sp. SA-2289 Pyroglutamyl 
peptidase 
Inhibition 
 
Source:  Solanki et al. (2008). 
21 
 
2.5.1  History of antibiotic development 
Interest in antimicrobial chemotherapy was kindled as soon as microorganisms were understood to 
be agents of infectious disease. In earlier times, plant products were sometimes used successfully in 
the treatment of disease, but neither doctors nor patients knew the basis for the action of these 
therapeutic agents. Many early medicines were used to cure protozoan diseases, rather than bacterial 
diseases. As early as 1619, it was known that malaria could be treated with the extract of cinchona 
bark (quinine) and that amoebic dysentery could be treated with ipecacuanha root (emetine) (Garrod 
and O'Grady, 1971; Greenwood, 2000). Only a few antibacterials, such as mercury, which was used 
to treat syphilis, were in use when the era of true chemotherapy began (Gangle, 2005). 
 Paul Ehrlich first hypothesized that dyes could be used as antimicrobial drugs in the early 
1900s, based on their differential affinities for various tissues. In 1904, Ehrlich and Shiga discovered 
that a red dye called trypanrot was effective against trypanosomes (Mølbak et al., 1999). It was 
around this time that arsenicals drew Ehrlich's interest. Ehrlich, along with Sahachiro Hata, in 1909, 
found that arsphenamine (named Salvarsan) was active against spirochetes and, therefore, was an 
effective cure for syphilis (Greenwood, 2000; Gangle, 2005). 
 The first truly effective class of antimicrobial drugs was the sulfonamides, discovered by 
Gerhard Domagk in 1935 (Greenwood, 2000). In 1932, two scientists at the Bayer Company, 
Mietzsch and Klarer, synthesized Prontosil red, a red dye bound to a sulfonamide group (Garrod and 
O'Grady, 1971; Greenwood, 2000). Domagk showed, in 1935, that infections in mice caused by 
hemolytic Streptococci were cured by Prontosil red (Garrod and O'Grady, 1971; Greenwood, 2000). 
 Unfortunately for Bayer, Prontosil red was shown to have no antibacterial activity in vitro. 
This lack of activity was explained by Tréfouël and colleagues in 1935 when they showed that 
Prontosil red is split in vivo into its component dye and sulfanilamide, the active antibacterial agent 
and a previously described molecule that was already in the public domain (Garrod and O'Grady, 
1971; Greenwood, 2000). From that point, sulfanilamide was manufactured by a number of 
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companies and work was begun to modify the molecule to enhance performance, leading to 
decreased side effects and a broader spectrum of action (Garrod and O'Grady, 1971; Greenwood, 
2000). 
 Although penicillin was the first natural antibiotic to be discovered, the idea of using 
microorganisms therapeutically was not new. Fungi had been used in poultices for many years, and 
by 1899, a product called pyocyanase, which was an extract from Pseudomonas aeruginosa, was 
used in the treatment of wounds (Garrod and O’Grady, 1971). Penicillin was first isolated from 
Penicillium notatum in 1928 by Alexander Fleming in 1929 (Demian, 1999), but he was unable to 
isolate and purify enough drugs to be of any use. By 1941, Ernst Chain, Howard Florey, and Norman 
Heatley had shown the therapeutic value of penicillin (Chain et al., 1940), but they were also unable 
to produce enough penicillin for commercial use. Collaboration with Andrew Moyer and Robert 
Coghill (Moyer and Coghill, 1946) at the USDA's Northern Regional Research Laboratory in Illinois 
led to much higher production yields of penicillin by 1943. After a worldwide search for Penicillium 
strains that could produce more penicillin, Raper and Fennel (Raper, 1946) found a strain of 
Penicillium chrysogenum on a moldy cantaloupe at a local market that was capable of even higher 
yields of penicillin (Demian, 1999). 
 A series of different antibiotics were quickly discovered after penicillin came into use. In 
1940, Selman Waksman began searching for antibiotic compounds produced by soil microorganisms 
(Greenwood, 2000). In 1943, one of Waksman's students discovered streptomycin (Schatz, 1944), 
leading to a flood of researchers combing the world for new drugs. It was in this same period that 
Hotchkiss and Rene Dubos, (1941) discovered gramicidin, the first antibiotic active against gram-
positive bacteria. Chlortetracycline, chloramphenicol, and others were discovered shortly thereafter 
(Garrod and O'Grady, 1971). Many discoveries were of drugs that were too toxic for human use, or 
that had already been discovered. Nevertheless, this work did lead to many new drugs and within 
only 10 years, drugs comprising the major classes of antibiotics were found (Greenwood, 2000). In 
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addition to soil, many of these drugs were discovered by isolating the producing microorganisms 
from interesting and unusual sources. (Garrod and O'Grady, 1971). 
 In 1962, one of the later discoveries was a synthetic drug, nalidixic acid, the first of the 
quinolones to be described, and although not therapeutically important by itself, modification of 
nalidixic acid led to the production of the highly effective fluoroquinolones. Members of this class, 
such as ciprofloxacin, norfloxacin, enrofloxacin, and ofloxacin, have become very important in the 
treatment of diseases in both humans and animals (Mitsuhashi, 1993). Since the 1960's, there have 
been few discoveries of new antibiotic drugs. The drugs developed since have mostly been chemical 
modifications of existing drugs. These modifications have been very useful in treating infectious 
diseases, leading to enhanced killing of pathogens, increased spectrum of action, reduced toxicity, 
and reduced side effects. Unfortunately, since the 1970's, only one new class of antibiotics has been 
introduced (Lipsitch, 2002) and a recent trend in antibiotic therapy has been to employ combinations 
of drugs with different mechanisms of action, in order to increase their effectiveness and to 
overcome the problem of drug resistance (Gangle, 2005). 
 
2.6 Development of resistance to antimicrobial agent 
Antibiotics have long been considered the “magic bullet” that would end infectious disease. 
Although they have improved the health of countless numbers of humans and animals, many 
antibiotics have also been losing their effectiveness since the beginning of the antibiotic era. Bacteria 
have adapted defenses against these antibiotics and continue to develop new resistances, even as we 
develop new antibiotics. In recent years, much attention has been given to the increase in antibiotic 
resistance. As more microbial species and strains become resistant, many diseases have become 
difficult to treat, a phenomenon frequently ascribed to both indiscriminate and inappropriate use of 
antibiotics in human medicine. However, the use of antibiotics and antimicrobials in raising food 
animals has also contributed significantly to the pool of antibiotic resistant organisms globally and 
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antibiotic resistant bacteria are now found in large numbers in virtually every ecosystem on earth. 
There is no doubt that the use of antibiotics provides selective pressure that result in antibiotic 
resistant bacteria and resistance genes (Gangle, 2005). While some resistant bacteria are found 
naturally in the environment, pathogens and nonpathogens are released into the environment in 
several ways, contributing to a web of resistance that includes human, animal, and the environment, 
essentially the biosphere (Gangle, 2005). 
 There is evidence that although resistant microorganisms existed in nature before the use of 
antibiotics, such microorganisms were mostly absent from human flora (Hughes and Datta, 1983). 
However, in the intervening years, antibiotic resistant microorganisms have become frighteningly 
common. Almost as soon as antibiotics were discovered, researchers began to find microorganisms 
resistant to the new drugs. Even by 1909, when Ehrlich first began to study dyes and arsenicals, he 
found drug resistant trypanosomes (Greenwood, 2000). Resistant strains of Staphylococcus aureus in 
hospitals grew from less than 1% incidence, when penicillin first came into use, to 14% in 1946, to 
38% in 1947, to more than 90% today (Greenwood, 2000). Worldwide, ampicillin and penicillin 
resistance can be found together in more than 80% of S. aureus strains (O'Brien, 1987). After World 
War II, sulfonamides were widely used to treat Shigella infections in Japan, but by 1952, only 20% 
of isolates were susceptible. As the Japanese began to switch to tetracycline, chloramphenicol, and 
streptomycin, Shigella strains that were multiple-resistant quickly began to appear (Falkow, 1975). 
Within 30 years of their discovery, sulfonamides ceased to be an effective treatment for 
meningococcal disease (O'Brien, 1987; Gangle, 2005).  
 In general, as stated above, resistance has been found in many organisms, but some 
pathogens are of particular recent concern. These pathogenic organisms are becoming increasingly 
more common, especially with the greater frequency of travel worldwide and increase in the 
population of the elderly, both in the United States and in many of the developed countries 
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worldwide (Melhus and Tjernberg, 1996). Some specific examples of microbial species that have 
developed significant resistance are cited as follows Enterococcus spp. 
 The enterococci are a group of gram-positive cocci that are part of the normal resident flora 
of both humans and some animals (Melhus and Tjernberg, 1996). They are generally not considered 
virulent; however, their intrinsic resistance to many antibiotics (including cephalosporins, penicillin, 
and aminoglycosides) has made them important opportunistic pathogens and one of the most 
common causes of nosocomial infections (Gangle, 2005). Although the enterococci are opportunistic 
pathogens, they are a frequent cause of urinary tract infections, bacteremia, and endocarditis, all of 
which can be difficult to treat due to resistance (Melhus and Tjernberg, 1996). Mortality rates in 
enterococcal bacteremia can reach 70% (Melhus and Tjernberg, 1996; Gangle, 2005). 
 The traditional method of treatment has been a combination of an aminoglycoside and 
ampicillin or a glycopeptide. By the 1970's, only ampicillin and vancomycin (a glycopeptide) were 
effective treatment options in most cases (Frieden et al., 1993). As of 2000, high level resistance to 
ampicillin and aminoglycosides was common, leaving vancomycin as the treatment of last resort 
(Jeljaszewicz et al., 2000). In one study in New York City, Frieden et al. (1993) found that 98% of 
vancomycin resistant enterococci (VRE) infections were acquired nosocomially and 19% of these 
were resistant to all antibiotics. Although vancomycin has been used in humans for more than 40 
years, VRE were not generally considered a clinical problem until recently. The first report of VRE 
in the lab was in 1969, but the first clinical cases were not seen until 1986 in England and in 1988 in 
New York City (Frieden et al., 1993). Since then, the frequency of VRE infections has vastly 
increased, becoming a major health problem. In 1998, it was reported that approximately 20% to 
40% of enterococcal nosocomial infections were vancomycin resistant (Khachatourians, 1998). A 
recently approved drug for the treatment of VRE is the streptogramin combination of 
quinupristin/dalfopristin; although only approved since 1999, there have already been reports of 
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sporadic resistance in human isolates and resistance is quite common on retail foods and in food 
animals (Gangle, 2005).  
 Antibiotic resistance is on the rise in E. coli. O'Brien et al. (1987) reported an incidence for 
sulfonamide resistance of between 21% and 85%, ampicillin resistance between 17% and 72%, 
tetracycline resistance between 24% and 60%, and trimethoprim resistance between 1% and 4%. 
Resistance to fluoroquinolones was rare for many years, but since the early 1990s, this has been on 
the rise; in one study in Spain, the incidence of resistance was shown to have reached 22% and more 
than a third of those isolates were resistant to three or more other antibiotics (Garau et al., 1999). 
 
2.7 Mechanisms of antibiotic action and resistance 
There are several major classes of antibiotics; they can be categorized based on their mode of 
antibacterial action. In general, antibiotics can be defined as those that inhibit cell wall synthesis, 
those that inhibit protein synthesis, and those that inhibit nucleic acid synthesis. A summary of the 
major antibiotic classes is shown in Table 2.2. The selective toxicity of antibiotics lies in the 
differences in cellular structures between eukaryotic and prokaryotic cells. However, differences in 
cellular structure among bacterial species can lead to resistance to certain antibiotics (Gangle, 2005). 
 The definition of bacteria as resistant or susceptible is critical for clinicians. It is also very 
important to note the difference between intrinsic and acquired resistance to an antibiotic. Intrinsic 
resistance can best be described as resistance of an entire species to an antibiotic, based on inherent 
(and inherited) characteristics requiring no genetic alteration. This is usually due to the absence of a 
target for the action of a given antibiotic or the inability of a specific drug to reach its target. For 
example, mycoplasmas are always resistant to β-lactam antibiotics since they lack peptidoglycan 
(which the β-lactams act upon) (Gangle, 2005). Similarly, the outer membrane of gram negative cells 
can prevent an antibiotic from reaching its target. For example, Pseudomonas aeruginosa exhibits 
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high intrinsic resistance to many antibiotics due to its drug efflux pumps and restricted outer 
membrane permeability (Gangle, 2005). 
 Acquired resistance can arise either through mutation or horizontal gene transfer. Presence of 
the antibiotic in question leads to selection for resistant organisms, thereby shifting the population 
towards resistance. The major mechanisms of acquired resistance are the ability of the 
microorganisms to destroy or modify the drug, alter the drug target, reduce uptake or increase efflux 
of the drug, and replace the metabolic step targeted by the drug (Gangle, 2005). 
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Table 2.2: Major classes of antibiotics and some examples  
Inhibitors of: 
 
 
Cell Wall Synthesis β-lactams Glycopeptides    
 Penicillins 
 
Vancomycin    
 Cephalosporins 
 
Avoparcin    
 Carbapenems 
 
    
Protein Synthesis Aminoglycosides Chloramphenicol Tetracyclines Macrolides Streptogramins 
 Streptomycin   Erythromycin Virginiamycin 
 
 Neomycin   Azythromycin Quinupristin-Dalfopristin 
 
 Kanamycin 
 
 
  Clarithromycin Pristinamycin 
 Gentamicin 
 
    
Nucleic Acid  
Synthesis 
Sulfonamides 
(diaminopyrimidines) 
Quinolones    
 Sulfamethoxazole Ciprofloxacin 
 
   
 Trimethoprim 
 
Norfloxacin    
Source: Gangle (2005). 
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2.7.1 Inhibitors of cell wall synthesis 
There are two major groups of cell wall synthesis inhibitors, the β-lactams and the glycopeptides. As 
bacterial cell walls are wholly unlike the membranes of eukaryotes, they are an obvious target for 
selectively toxic antibiotics. The β-lactams include the penicillins, cephalosporins, and the 
carbapenems. These agents bind to the penicillin binding proteins (PBP's) that cross-link strands of 
peptidoglycan in the cell wall (Greenwood, 2000). In gram negative cells, this leads to the formation 
of fragile spheroplasts that are easily ruptured; in Gram positive cells, autolysis is triggered by the 
release of lipoteichoic acid (Greenwood, 2000). The mechanism of β-lactam resistance is via the 
action of the β-lactamases. These enzymes catalyze hydrolysis of the β-lactam ring and, thereby, 
inactivating these antibiotics (Greenwood, 2000). Many bacteria contain chromosomally encoded β-
lactamases necessary for cell wall production and it is only through over-production of these 
enzymes that resistance occurs (Greenwood, 2000). β-lactamases encoded on plasmids or other 
transmissible elements can lead to such overproduction and, therefore, to resistance (Normark and 
Normark, 2002). There are also some bacteria that possess altered PBP's that result in reduced 
penicillin binding (Greenwood, 2000). 
 Since the discovery of penicillin and resistant bacteria, various new versions of the β-lactams 
have been used that have different spectrums of activity and different susceptibility to β-lactamases. 
Since the 1970s, several compounds, such as clavulanic acid, have been discovered that have the 
ability to bind irreversibly to β-lactamases and, thereby, inhibit their action. Combinations of these 
compounds with β-lactam drugs have been very successful in treatment of diseases (Bryan, 1984). 
The glycopeptides are a group of antibiotics that include vancomycin, avoparcin, and others that bind 
to acyl-D-alanyl-D-alanine. Binding of this compound prevents the addition of new subunits to the 
growing peptidoglycan cell wall (Bryan, 1984). These drugs are large molecules that are excluded 
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from gram negative cells by the outer membrane, thus limiting their action to gram positive 
organisms (Bryan, 1984). 
 Glycopeptide resistance was long thought to be rare, but has recently been shown to be quite 
common (Bryan, 1984). Resistance in enterococci has developed through newly discovered enzymes 
that use D-alanyl-D-lactate in place of acyl-D-alanyl-Dalanine, allowing cell wall synthesis to 
continue (Greenwood, 2000). Other mechanisms of resistance involve the over-production of 
peptidoglycan precursors which overwhelm the drug (Greenwood, 2000). 
 
2.7.2 Inhibitors of protein synthesis 
There are many types of antibiotics that inhibit bacterial protein synthesis. These drugs take 
advantage of structural differences between bacterial ribosomes and eukaryotic ribosomes. The 
aminoglycoside antibiotics are a group whose mechanism of action is not completely understood. 
The three major groups of aminoglycosides are the streptomycins, neomycins, and kanamycins 
(Greenwood, 2000). These drugs enter bacterial cells by an active transport that involves quinones 
that are absent in anaerobes and streptococci, thus excluding these organisms from the spectrum of 
action. 
 Streptomycins act by binding to the 30S ribosomal subunit; kanamycins and neomycins bind 
to both the 50S subunit and to a site on the 30S subunit different from that of streptomycin 
(Greenwood, 2000). Activity involving initiation complexes and cell membrane proteins that 
contribute to cell death plays a role in the action of these antibiotics, but this is poorly understood 
(Bryan, 1984; Greenwood, 2000). 
 There are three mechanisms of aminoglycoside resistance that have been identified to date. 
The first involves only streptomycin. Since streptomycin; binds to one particular protein on the 
ribosome, alteration of this protein, even by a single amino acid in its structure, confers high-level 
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resistance to the drug (Bryan, 1984). The third mechanisms involve decreased uptake of the 
antibiotic and in one of these the cell membrane is altered, preventing active transport of the drug 
(Bryan, 1984). In the other, one of many enzymes alters the antibiotic as it enters the cell, causing a 
block in further active transport (Bryan, 1984). 
 Chloramphenicol is a broad-spectrum antibiotic that, although naturally occurring, is 
produced by chemical synthesis. Chloramphenicol inhibits peptide bond formation on 70S ribosomes 
(Bryan, 1984). This drug is especially useful in that it can penetrate eukaryotic cells and 
cerebrospinal fluid, making it a drug of choice for treatment of meningitis and intracellular bacterial 
infections such as those caused by Chlamydia (Greenwood, 2000). It is not in widespread use, 
however, because of potentially fatal side-effects, namely, aplastic anemia (Greenwood, 2000). 
Resistance to chloramphenicol is conferred by the enzyme chloramphenicol acetyl-transferase; a 
number of these enzymes have been discovered, each altering the chloramphenicol molecule to 
prevent binding to the bacterial ribosome (Greenwood, 2000). Chloramphenicol resistance in gram 
negative cells can also arise from alteration in outer membrane permeability that prevents the drug 
from entering the cell (Bryan, 1984). 
 The tetracyclines are another group of broad-spectrum antibiotics that inhibit bacterial protein 
synthesis. They are brought into the cell by active transport and, once there, bind to the 30S subunit 
to prevent binding of aminoacyl tRNA (Roberts, 1996). Resistance to the tetracyclines occurs via 
three mechanisms. First, production of a membrane efflux pump removes the drug as rapidly as it 
enters and there are several genes encoding these pumps (Roberts, 1996). Second, several ribosome 
protection proteins act to prevent tetracycline from binding to the ribosome, thus conferring 
resistance (Roberts, 1996). Third, a protein found only in Bacteroides spp., enzymatically inactivates 
tetracycline (Roberts, 1996). Interestingly, efflux pump inhibitors have recently been discovered that 
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may allow combinations of these inhibitors and tetracyclines to be used against previously resistant 
strains (Chopra, 2002). 
 The macrolides are a group of antibiotics commonly used to treat gram positive and 
intracellular bacterial pathogens. Erythromycin was the first of these (Gaynor, 2003), and several 
other important macrolides have been discovered since, including clarithromycin and azithromycin. 
Azithromycin has a longer plasma half-life which allows treatment with a single dose for some 
pathogens or a once daily dose for others. Clarithromycin has enhanced absorption and causes less 
gastrointestinal discomfort (Gaynor, 2003). It was originally believed that erythromycin inhibited 
protein synthesis by competing with amino acids for ribosomal binding sites, but newer research 
show several mechanisms are involved (Garrod and O'Grady, 1971). The macrolides are now 
believed to promote dissociation of tRNA from the ribosome, inhibit peptide bond formation, inhibit 
ribosome assembly, and prevent amino acid chain elongation (Gaynor, 2003). 
 There are two major mechanisms of macrolide resistance. First, an efflux pump has been 
found that removes the drug from the cell (Gaynor, 2003). Second, modification of the ribosome can 
confer resistance; mutations at several sites of the ribosome can allosterically prevent macrolide 
binding and a common alteration is dimethylation of one nucleotide on the 23S rRNA. This 
dimethylation not only prevents macrolide binding, but also confers resistance to lincosamide and 
streptogramin antibiotics (Gaynor, 2003). 
 The streptogramins are another class of antibiotic that inhibits bacterial protein synthesis, 
mostly in gram positive organisms (due to decreased permeability of the gram negative outer 
membrane). These antibiotics are actually combinations of structurally different drugs; types A and 
B that act synergistically (Johnson et al., 2002). These compounds bind to separate sites on the 50S 
subunit. Type A drugs block attachment of substrates at two sites on the 50S subunit, whereas type B 
drugs cause release of incomplete protein chains. The synergistic effect arises from a conformational 
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change induced by the binding of a type A drug which significantly increases affinity of type B drugs 
(Johnson et al., 2002). Streptogramins currently in use include virginiamycin, pristinamycin, and 
quinupristin/dalfopristin (Johnson et al., 2002; Gangle, 2005). Resistance to streptogramin antibiotics 
can be found in several forms. Efflux pumps for both type A and B streptogramins have been 
identified. Type A streptogramins can be inactivated by one of the virginiamycin acetyl-transferases, 
and several enzymes have been identified that can inactivate type B streptogramins (Johnson et al., 
2002; Gangle, 2005). Alteration of bacterial ribosomal proteins or RNA can also confer resistance. A 
common mutation is the dimethylation of one nucleotide on the 23S rRNA, mentioned previously, 
that gives rise to resistance to type B drugs, as well as macrolides and lincosamides (Johnson et al., 
2002; Gangle, 2005). 
 
2.7.3 Inhibitors of nucleic acid synthesis 
The sulfonamides and the diaminopyrimidines should be discussed together, in that both only 
indirectly inhibit nucleic acid synthesis by inhibiting folate synthesis. Folate is a coenzyme necessary 
for the synthesis of purines and pyrimidines. Although both types of drugs are useful on their own, 
they exhibit a synergistic effect when combined. Sulfonamides are currently not used commonly in 
medicine, but the combination drug trimethoprim-sulfamethoxazole is sometimes used in the 
treatment of urinary tract infections (Greenwood, 2000). Sulfonamides serve as an analog of p-
aminobenzoic acid; therefore, they competitively inhibit an early step in folate synthesis 
(Greenwood, 2000). Diaminopyrimidines, of which trimethoprim is the most common, inhibit 
dihydrofolate reductase, the enzyme that catalyzes the final step in folate synthesis (Greenwood, 
2000). 
 There are several resistance mechanisms microorganisms employed against each of the anti-
folate drugs. For example, sulfonamides are rendered ineffective by over-production of p-
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aminobenzoic acid or production of an altered dihydropteroate synthetase. The substrate for 
dihydropteroate synthetase is p-aminobenzoic acid, and the altered form has a much lower affinity 
for sulfonamides than for p-aminobenzoic acid (Then, 1982). Trimethoprim resistance can also result 
from several mechanisms, e.g., over-production of dihydrofolate reductase or production of an 
altered, drug-resistant form can lead to resistance (Bryan, 1984). In addition, both drugs can be 
enzymatically inactivated, resulting in resistance (Then, 1982). 
 The quinolones are a chemically varied class of broad-spectrum antibiotics widely used to 
treat many diseases, including gonorrhea and anthrax. Drugs in this class include nalidixic acid, 
norfloxacin, and ciprofloxacin. These drugs are commonly used and, worldwide, more ciprofloxacin 
is consumed than any other antibacterial agent (Acar, and Goldstein, 1997). Quinolones inhibit 
bacterial growth by acting on DNA gyrase and topoisomerase IV, which are necessary for correct 
functioning of supercoiled DNA (Greenwood, 2000). Although quinolones target both enzymes, in 
gram negative organisms the primary target is DNA gyrase and, in gram positive organisms, the 
primary target is topoisomerase IV (Ruiz, 2003). 
 There are three main mechanisms of resistance to quinolones. Resistance to some quinolones 
occurs with decreased expression of membrane porins (Normark and Normark, 2002). Cross-
resistance to other drugs requiring these porins for activity also results from these changes. A second 
mechanism of resistance is expression of efflux pumps in both gram negative and gram positive 
organisms (Normark and Normark, 2002), and the third is alteration of the target enzymes. Several 
mutations have been described in both quinolone target proteins that result in reduced binding 
affinities (Ruiz, 2003). It is believed that high-level quinolone resistance is brought about by a series 
of successive mutations in the target genes, rather than a single mutation (Normark and Normark, 
2002; Gangle, 2005). 
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2.8 Enzymatic aspect of antibiotic resistance 
Antibiotic resistance is now well recognized as a major problem in the treatment of infections in 
hospitals and, with increasing and alarming frequency, in the community. Resistance can be active 
(i.e., the result of a specific evolutionary pressure to adapt a counterattack mechanism against an 
antibiotic or class of antibiotics) or passive (where resistance is a consequence of general adaptive 
processes that are not necessarily linked to a given class of antibiotic; e.g., the nonspecific barrier 
afforded by the outer membrane of Gram-negative bacteria). Bacteria achieve active drug resistance 
through three major mechanisms: (1) efflux of the antibiotic from the cell via a collection of 
membrane-associated pumping proteins; (2) modification of the antibiotic target (e.g., through 
mutation of key binding elements such as ribosomal RNA or even by reprogramming of biosynthetic 
pathways such as in resistance to the glycopeptide antibiotics); and (3) via the synthesis of modifying 
enzymes that selectively target and destroy the activity of antibiotics. All of these mechanisms 
require new genetic programming by the cell in response to the presence of antibiotics. In fact, in 
several cases, the antibiotics or their action actually genetically regulate the expression of resistance 
genes is shown in Table 2.3. Therefore, bacterial cells expend a considerable amount of energy and 
genetic space to actively resist antibiotics (Wright, 2005). 
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Table 2.3: Enzymatic strategies of antibiotic inactivation 
Strategy Type Antibiotics Affected 
Hydrolysis  β-Lactams 
  Macrolides 
Group transfer Acyl Aminoglycoside 
  Chloramphenicol 
  Type A streptogramin 
 Phosphoryl Aminoglycoside 
  Macrolide 
  Rifamycin 
  Peptide 
 Thiol Fosfomycin 
 Nucleotidyl Aminoglycoside 
  Lincosamide 
 ADP-ribosyl Rifamycin 
 Glycosyl Macrolide 
  Rifamycin 
Other Redox Tetracycline 
  Rifamycin 
  Type A streptogramin 
 Lyase Type B streptogramin 
Source: Wright (2005). 
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CHAPTER THREE 
 
MATERIALS AND METHODS 
3.1 Test bacteria 
The test bacteria that were used in this study includ reference, environmental as well as clinical 
isolates. The typical reference strains were as follows:  
Gram-positive: Staphylococcus aureus ATCC 6538, Streptococcus faecalis ATCC 29212, 
Streptococcus pyogens ATCC 10389, Bacillus cereus ATCC 10702, Bacillus pumilus ATCC 14884, 
Acinetobacter calcaoceuticus UP and Acinetobacter calcaoceuticus  subsp anitratus CSIR.  
Gram-negative: Escherichia coli ATCC 8739, Escherichia coli ATCC 25922, Pseudomonas 
aeruginosa ATCC7700, Pseudomonas aeruginosa ATCC 19582, Proteus vulgaris ATCC 6830, 
Proteus vulgaris CSIR 0030, Enterobacter cloacae ATCC 13047, Serratia marscens ATCC 9986, 
Klebsiella pneumonia ATCC 10131 and Klebsiella pneumonia ATCC 4352.  
Environmental isolates: Klebsiella pneumonia, Bacillus subtilis, Shigella flexineri, Salmonella sp, 
Staphylococcus epidermidis, Pseudomonas aeruginosa, Proteus vulgaris, Enterococcus faecalis, 
Eschechia coli, Staphlococcus aureus and Bacillus stearothermophillus were kindly provided by Dr. 
AO Olaniran of the University of KwaZulu-Natal. 
Clinical isolates: Includes the following; staphylococcal strains isolated from septic wound 
abrasion: Staphylococcus aureus OKOH1, Staphylococcus aureus OKOH2A, Staphylococcus aureus 
OKOH3, and Staphylococcus sciuri OKOH2B with Gene Bank accession numbers Eu244633, 
Eu244634, Eu244635 and Eu244636 respectively. 
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3.2 Source of Streptomyces 
The Streptomyces used in this study were isolated from the Nahoon beach (Ogunmwonyi, 2008) and 
stored in the culture collection of the Applied and Environmental Microbiology Research Group 
(AEMREG), University of Fort Hare. Eighty-four (84) Actinomycetes isolates were obtained and 
tentatively grouped into 15 generic morphotypes. Of these, 30 isolates belonging to the Streptomyces 
morphotypes were selected for preliminary screening for antibacterial activity and these were coded 
as NB003, NB008, NB009, NB012, NB013, NB017, NB018, NB022, NB023, NB025, NB031, 
NB033, NB035, NB037, NB039, NB041, NB042, NB043, NB046, NB050, NB051, NB052, NB056, 
NB059, NB061, NB063, NB070, NB073, NB078 and NB084. 
 
3.3 Preparation of Streptomyces suspension  
The test Streptomyces suspensions were prepared by suspending a loopful of pure Streptomyces 
colony in 2 ml sterile normal saline, vortexed to homogenize and stored at 4 
o
C until ready for use. 
This suspension was used as Streptomyces inoculants in all cultivations.                                                                                                                                                           
 
3.4 Preparation of test bacteria 
All test bacteria were grown in Nutrient broth (biolab, Merck) and incubated at 37 
o
C for 24 hr and a 
total of 10 ml of the pure culture was centrifuged to pellet out the cells, washed twice with sterile 
physiological saline and the suspension adjusted to optical density 0.1 at 600nm which is equivalent 
to a cell population of about 10
6
 cells/ml on the McFarland standard. Bacteria suspension was stored 
in test tubes and refrigerated at 4 
o
C. These test bacteria were frequently checked for viability and re-
prepared when appropriate. 
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3.5 Streptomyces cultivation media composition  
Yeast Malt Broth (YMB) was used for the cultivation of the test Streptomyces and has the following 
composition: [Yeast extract 4 g/l (biolab, Merck), Malt extract broth10 g/l (Conda, Pronadisa), 
Glucose 4 g/l (Saarchem, Merck)]. Potato Dextrose Agar (PDA) [(Potato extract 4 g/l, Dextrose 20 
g/l, Agar 15.0 g/l (biolab, Merck)]. Nutrient Agar (NA) [(Meat extract 1 g/l, Yeast extract 2 g/l, 
Peptone 5 g/l, Sodium chloride 8 g/l, Agar 15 g/l (biolab, Merck)]. Nutrient Broth (NB) [(Meat 
extract 1 g/l, Yeast extract 2 g/l, Peptone 5 g/l, Sodium chloride 8 g/l (biolab, Merck)]. Mueller-
Hinton Agar (MHA) [(Meat infusion 5 g/l, Casein Hydrolysate 17.5 g/l, soluble starch 1.5 g/l, Agar 
14 g/l (biolab, Merck)]. These media were prepared according to the manufacturer instructions. 
 
3.6 Primary screening of actinomycetes for antibiotic production  
3.6.1 Preparation of preliminary test organism 
The test organisms used for preliminary screening were Escherichia coli ATCC 8739, Bacillus 
cereus ATCC 10702, Bacillus subtilis KZN and Candida albicans. Test bacteria were grown in 4.50 
ml Nutrient broth for 18 hrs, and then standardized to McFarland standard of 0.1 at OD 600nm. 
Candida albicans was grown on Potato dextrose agar (PDA) plate for 48 hr, then re-suspended in 
Nutrient broth and standardized to McFarland standard of 0.1 at OD 600nm before use. 
 
3.6.2 Preliminary screening  
Yeast malt broth (YMB) was prepared and 50 ml dispensed into 250 ml capacity flask, autoclaved, 
allowed to cool and inoculated with 0.5 ml actinomycetes suspension. Flasks were incubated at 28 
°C at 230 rpm for 8 days. Cultures were harvested by centrifugation at maximum speed for 15 min to 
obtain cell free extract which was used for preliminary screening for antibacterial activity. The 
preliminary screening was carried out by streaking method. Ten milliliter of the cell free extract was 
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incorporated into double strength 10 ml sterilized molten MHA at 50 °C, plates poured, allowed to 
set and then streaked upon by test bacteria and incubated at 37 °C for 24 hr. The same regimen was 
done with PDA for the test yeast, but incubation was at 28 
o
C for 24-48 hr. Control experiments were 
carried out using sterile nutrient broth in place of the cell free extracts.  
 
3.7 Secondary screening of fermentation product for antibiotic production  
3.7.1 Bulk fermentation and preparation of crude ethyl acetate extracts 
Based on the results of preliminary screening, 10 putative Streptomyces isolate were selected for the 
fermentation and assessment of antibiotic production. The putative Streptomyces isolates included 
NB003, NB008, NB009, NB012, NB017, NB022, NB046, NB063, NB078 and NB084. 
Fermentation for production of antibiotic and subsequent extraction of the antibiotics was done as 
described by Ilic et al. (2007) with modification. Yeast malt extract broth (YMB) was prepared and 
20 ml dispensed into 100 ml Erlenmeyer flask capacity, sterilized, allowed to cool and inoculated 
with 0.5 ml Streptomyces isolate suspension and incubated at 28 
o
C for 48 hr at 230 rpm. About 500 
ml of YMB was prepared in 1L Erlenmeyer flask and inoculated with the 48 hr old pre-culture of 
Streptomyces isolate and incubated for 10 days at 28 °C and 230 rpm. At the end of the incubation 
period, the culture was harvested by centrifugation at maximum speed for 15 min. The culture 
supernatant was extracted twice with equal volumes of ethyl acetate (1:1 v/v) and vaporized to 
dryness in a rotary evaporator at 50 °C. The extract was re-constituted in 50 % filter sterilized 
methanol to obtain the desired concentration at every stage of screening. 
 
3.7.2 Screening for antibacterial activity  
The crude ethyl acetate extracts was screened for antibacterial activity using the cup well agar 
diffusion method as described by Pandey et al. (2004). For this purpose 20 ml of sterilized molten 
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Mueller Hinton agar (MHA) in McCartney bottles was seeded with 50 µl of standardized test 
bacteria swirl gently and aseptically poured into petri plate and allowed to solidify. Sterile cork borer 
(6 mm diameter) was used to bore holes in the plate. About 100 µl of the crude ethyl acetate extract 
at a concentration of 10 mg/ml was carefully dispensed into bored holes. This was done in duplicate. 
Extracts were allowed to diffuse for about 2 hr before incubating. Plates were incubated at 37 °C for 
24 hr. The presence of a zone of inhibition around each well was indicative of antibacterial activity. 
Control experiment was carried out by loading 10 % methanol into control well against each test 
organism to ensure that it does not have activity against test bacteria. 
 
3.8 Determination of minimum inhibitory concentration (MIC) and minimum bactericidal 
concentration (MBC) of the extracts  
The MIC and MBC was determined using the broth micro dilution method as described by Eloff 
(1998) using test bacteria that have been standardized to optical density of 0.1 at 600 nm. Extracts 
were re-suspended in 10 % filter sterilized methanol to obtain a concentration of 40 mg/ml. Using a 
96-well microtitre plate, 100 µl double strength nutrient broth was dispensed into every well and 
labeled appropriately. 50 µl of extract was added into well 3, mixed carefully using pipette and 
diluted serially along the row to row 11. Addition of the standardized test bacteria into the 96-well 
microtitre plate was incorporated. Plates were covered and incubated at 37 °C for 18-24 hr. Control 
wells were loaded with nutrient broth and extract with no bacteria added (wells 1 A-H), broth and 
bacteria with no extract (wells 12 A-H), 10 % MeOH, broth and bacteria (wells 2 A-H) to ensure that 
10 % MeOH constitution solvent had no inhibitory effect on the test bacteria. Each extract was 
assayed in triplicate against test bacteria. Biolab micro plate reader (Model 680 S/N 19138) was used 
to quantify the optical density of the reactants in each well. A graph of optical densities of wells 
contents was plotted against extracts concentrations. From the graph the MICs of extracts against test 
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bacteria were estimated. Also, to complement this assay, bacterial growth was confirmed by adding 
50 μl of 0.2 mg/ml solution of 2[4-iodophenyl]3[4-nitrophenyl]-5-phenyl-2H-tetrazolium chloride 
(INT) in each test well, and the plate was incubated further for at least 1hr at 37°C, to ensure 
adequate colour development. The lowest concentration in which there was a definite decrease in 
colour was taken as the MIC of that extract, for that particular organism. 
 The MBC of active extracts was determined by streaking on Mueller Hinton Agar plates from 
wells that showed growth inhibition. The concentration of extract in the wells where there was no 
growth on plate was considered as the MBC. 
 
3.9 Determination of rate of kill 
The method of Spangler et al. (1997) was adopted for the time-kill assay against some selected 
susceptible bacteria. Viable counts of the test bacteria were first determined.  Initial inocula of 10
5
 to 
10
6 
cfu/ml were prepared from 100 µl aliquots of test bacteria in normal saline and this was verified 
by performing colony counts. Eighty microliter (80 µl) volume of suspension of known cell density 
of selected test bacteria was added to 10 ml of Nutrient broth in McCartney bottles of known 
concentration (relative to MIC) of each of the extracts. Time kill assay of each extract against the 
selected test bacteria were determined using the following extract concentrations: MIC, 2 × MIC, 3 × 
MIC and 4 × MIC and the reactants bottles were incubated in a rotary incubator at 37 °C. The time 
kill kinetics were determined at 0 hr, 3 hr and 6 hr. Exactly 0.5 ml volume of the reaction mixture 
was withdrawn at the appropriate time and transferred to 4.5 ml of nutrient broth recovery medium 
containing 3 % sodiumthioglycolate or 3 % "Tween-80" to neutralize the effects of the extracts 
carry-overs from the test suspensions and diluted serially in sterile nutrient broth. Approximately 100 
µl aliquots of each dilution were plated out for viable counts by pour plate technique. Each 
experiment was done in duplicate, and the mean of two almost identical results was calculated. Only 
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plates yielding 30 to 300 colonies were selected for counting. Data were analyzed by expressing 
growth as the log10 colony forming unit per milliliter (cfu/ml). Bacteriostatic activity was defined as 
a reduction of 0 to 3 log10 cfu/ml, and bactericidal activity was defined as a reduction of ≥ 3 log10 
cfu/ml at 3 hr and 6 hr compared to that at 0 hr (Spangler et al., 1997). McCartney bottles containing 
broth and test organism without extract was used as growth control in each experiment. 
 
 3.10 Characterization of crude extracts 
 3.10.1 Infrared spectroscopy 
The Infrared (IR) spectra of the crude extracts were measured (as KBr discs) between 400-4000cm
-
1
on Perkin Elmer 2000 FT-IR spectrophotometer. The important IR bands, such as ʋ (C-N), ʋ (O-H), 
ʋ (C-H), ʋ (C=C), ʋ (N-H), ʋ (C-O) and  (C-H) symmetric and asymmetric stretching, and stretching 
frequencies were studied to determine the presence of functional group in the ethyl acetate crude 
extracts. 
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CHAPTER FOUR 
 
RESULTS 
 
4.1 Preliminary screening of tentative isolates of Streptomyces 
The result of preliminary screening is as shown in Table 4.1. Of the thirty putative Streptomyces 
screened, twelve showed varying levels of antimicrobial activities against the four test organisms 
including Escherichia coli ATCC 8739, Bacillus cereus ATCC 10702, Bacillus pumilus ATCC 
14884 and Candida albicans. NB025 and NB042 showed activity against Candida albicans only, 
while NB003, NB008, NB009, NB012, NB017, NB046, NB063 and NB078, showed broad spectrum 
activity against the tested bacteria. Isolate NB022 showed only a narrow spectrum activity against 
the test Gram positive, and isolate NB084 was active against all test bacteria and Candida albicans. 
Eighteen of the isolate viz. NB013, NB018, NB023, NB031, NB033, NB035, NB037, NB039, 
NB041, NB043, NB050, NB051, NB052, NB056, NB059, NB061, NB070 and NB073 did not show 
any activity against the test organisms. 
 
 
Table 4.1: Results of preliminary screening of antimicrobial activities of the Streptomyces 
isolates.  
Test 
Streptomyces 
Antimicrobial activity  
E. coli B. cereus B. subtilis C. albicans 
NB003 + + + _ 
NB008 + + + _ 
NB009 + + + _ 
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NB012 + + + _ 
NB013 _ _ _ _ 
NB017 + + + _ 
NB018 _ _ _ _ 
NB022 _ + + _ 
NB023 _ _ _ _ 
NB025 _ _ _ + 
NB031 _ _ _ _ 
NB033 _ _ _ _ 
NB035 _ _ _ _ 
NB037 _ _ _ _ 
NB039 _ _ _ _ 
NB041 _ _ _ _ 
NB042 _ _ _ + 
NB043 _ _ _ _ 
NB046 + + + _ 
NB050 _ _ _ _ 
NB051 _ _ _ _ 
NB052 _ _ _ _ 
NB056 _ _ _ _ 
NB059 _ _ _ _ 
NB061 _ _ _ _ 
NB063 + + + _ 
NB070 _ _ _ _ 
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NB073 _ _ _ _ 
NB078 + + + _ 
NB084 + + + + 
 
Legend:  + = extract active against test organism; - = extract inactive against test organism. 
 
 4.2 Screening of fermentation products for antibacterial activity 
The results of the screening of the ethyl acetate crude extracts of the selected ten putative 
Streptomyces for antibacterial activities are presented in Table 4.2. These extracts showed activities 
against a minimum of 6 test bacteria and maximum of 26 among the 32 test bacteria amounting to 
approximately 18.8 to 81.3 % antibacterial activities (Table 4.2).  
NB003 extracts showed activity against twenty-six test bacteria with zones of inhibition 
ranging from 10 mm to 22 mm, while NB008 and NB009 extracts showed activity against 25 and 15 
test bacteria respectively (Table 4.2). Isolates NB012, NB017, NB022, NB046, NB063, NB078 and 
NB084 extracts were active against 19, 6, 17, 19, 18, 20 and 12 test bacteria respectively with zones 
of inhibition ranging from 9-32 mm diameter (Table 4.2). 
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 Table 4.2: Antibacterial activities of fermentation products of the selected putative Streptomyces isolates 
Test bacteria Gram 
reaction 
Antibacterial activity (zone of inhibition in mm) (Mean ± SD) 
NB003 NB008 NB009 NB012 NB017 NB022 NB046 NB063 NB078 NB084 
Escherichia  coli   ATCC 8739 - 12 ± 0.2 0 ± 0 15 ± 0.5 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Escherichia  coli ATCC 25922 - 13 ± 0.1 12 ±0.4 0 ± 0 17 ± 1.2 10 ± 0.6 11 ± 1.2 0 ± 0 13 ± 1.5 0 ± 0 0 ± 0 
Pseudomonas aeruginosa ATCC 19582 - 10 ± 0.2 13 ± 0.5 0 ± 0 0 ± 0 0 ± 0 0 ± 0 18 ± 0.5 18 ± 0.1 0 ± 0 0 ± 0 
Staphylococcus aureus  ATCC6538 + 10 ± 1.2 0 ± 0 0 ± 0 22 ± 0.2 0 ± 0 13 ± 0.4 10 ± 1.2 0 ± 0 0 ± 0 10 ± 1.0 
Streptococcus faecalis  ATCC 29212 + 0 ± 0 12 ± 1.1 0 ± 0 17 ± 1.5 0 ± 0 0 ± 0 16 ± 1.4 16 ± 0.5 0 ± 0 14 ± 1.0 
Bacillus cereus ATCC 10702 + 13 ± 0.2 14 ± 0.4 18 ± 1.5 15 ± 1.4 12 ± 0.1 14 ± 0.1 15 ± 1.0 15 ± 0.2 12 ± 0.5 12 ± 1.0 
Bacillus pumilus ATCC 14884 + 14 ± 1.2  11 ± 0.8 18 ± 0.5 19 ± 2.1 0 ± 0 14 ± 1.0 15 ± 1.2 15 ± 0.5 13 ± 0.2 16 ± 0.1 
Pseudomonas aeruginosa ATCC 7700 - 15 ± 2.1 12 ± 0.5  0 ± 0 0 ± 0 0 ± 0 0 ± 0 10 ± 0.4  16 ± 0.8 0 ± 0 0 ± 0 
Enterobacter cloacae ATCC 13047 - 14 ± 0.9 11 ± 0.5 0 ± 0 17 ± 1.4 0 ± 0 15 ± 1.5 0 ± 0 16 ± 1.1 13 ± 0.5 0 ± 0 
Klebsiella pneumonia   ATCC 10031 - 12 ± 0.8 13 ± 1.1 15 ± 1.5 18 ± 2.0 12 ± 0.1 13 ± 0.5 0 ± 0 17 ± 1.5 12 ± 0.6 16 ± 0.8 
Klebsiella pneumonia   ATCC 4352 - 12 ± 0.2 13 ± 0.4 15 ± 0.5 18 ± 0.9 12 ± 0.5 10 ± 0.4 18 ± 1.2 0 ± 0 12 ± 1.1 17 ± 1.5 
Proteus vulgaris ATCC 6830 - 14 ± 0.9 12 ± 0.8 13 ± 0.7 17 ± 0.3 0 ± 0 0 ± 0 17 ± 0.4 0 ± 0 14 ± 0.7 0 ± 0 
Proteus vulgaris CSIR 0030 - 0 ± 0 12 ± 0.2 0 ± 0 0 ± 0 0 ± 0 0 ± 0 12 ± 1.2 12 ± 0.9 11 ± 0.5 0 ± 0 
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Serratia marscens ATCC 9986 - 10 ± 0.5   12 ± 0.2 0 ± 0 0 ± 0 0 ± 0 0 ± 0 15 ± 0.4 15 ± 0.1 13 ± 0.5 9 ± 0.1 
Acinetobacter calcaoceuticus  UP + 15 ± 0.2 12 ± 0.1 16 ± 0.5 17 ± 1.1 0 ± 0 10 ± 0.5 14 ± 0.8 0 ± 0 13 ± 0.6 14 ± 0.2 
Acinetobacter calcaoceuticus subsp 
 anitratus  CSIR 
+ 15 ± 1.1 13 ± 1.2 0 ± 0 18 ± 1.4 0 ± 0 0 ± 0 15 ± 1.0 15 ± 1.2 13 ± 0.5 10 ± 0.2 
Klebsiella pneumonia   KZN - 12 ± 0.4 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 12 ±0.2 12 ±0.5 20 ± 2.1 0 ± 0 
Bacillus subtilis  KZN + 15 ± 1.0 12 ± 0.5 14 ± 0.5 22 ± 2.0 0 ± 0 12 ± 0.5 0 ± 0 10 ± 0.5 15 ± 0.4 0 ± 0 
Shigella flexineri   KZN - 0 ± 0 0 ± 0 11 ± 0.7 11 ± 0.8 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Salmonella sp KZN - 12 ± 0.5 12 ± 0.2 0 ± 0 0 ± 0 0 ± 0 0 ± 0 12 ± 0.1 0 ± 0 15 ± 0.5 0 ± 0 
Staphylococcus epiderdemis  KZN - 10 ± 0.8 0 ± 0 0 ± 0 20 ± 1.5 0 ± 0 12 ± 0.9 0 ± 0 17 ± 0.9 0 ± 0 0 ± 0 
Pseudomonas aeruginosa KZN - 0 ± 0 12 ± 0.6 10 ± 0.1 10 ± 0.5 0 ± 0 0 ± 0 0 ± 0 17 ± 0.7 11 ± 1.2 0 ± 0 
Proteus vulgaris  KZN - 14 ± 0.5 15 ± 1.0 12 ± 1.0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 12 ± 0.9 0 ± 0 
Enterococcus Faecalis  KZN  - 0 ± 0 0 ± 0 10 ± 0.9 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Escherichia  coli  KZN - 15 ± 0.1 14 ± 0.5 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Staphylococcus aureus  KZN + 17 ± 0.2 9 ± 0 0 ± 0 22 ± 0.5 0 ± 0 20 ± 0.8 16 ± 0.4 0 ± 0 0 ± 0 0 ± 0 
Staphylococcus aureus  OKOH1 + 22 ± 0 12 ± 0.5 0 ± 0 0 ± 0 10 ± 0.1 22 ± 0 0 ± 0 0 ± 0 10 ± 0.5 13 ± 0.9 
Staphylococcus aureus  OKOH 2A + 0 ± 0 0 ± 0 0 ± 0 29 ± 2.0 0 ± 0 12 ± 0.5 18 ±0.9 32 ± 1.5 0 ± 0 0 ± 0 
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*Diameter of zone of inhibition reported on susceptibility was based on the recommended guidelines by Clinical and Laboratory Standards 
Institute (2005). 
 
 
 
 
 
Staphylococcus sciuri   OKOH 2B + 12 ± 0.8 10 ± 0.5 11 ±0.9 0 ± 0 0 ± 0 13 ±0.4 17 ±0.6 17 ±0.2 0 ± 0 0 ± 0 
Staphylococcus aureus  OKOH 3 + 20 ± 1.2 17 ± 0.5 10 ± 0.2 14 ± 1.0 14 ± 0.8 27 ± 1.5 12 ± 0.5 0 ± 0 12 ± 0.9 15 ±0.1 
Micrococcus kristinae + 19 ± 0.9 15 ± 0.8 12 ± 0.5 0 ± 0 0 ± 0 25 ± 1.5 16 ± 0.9 12 ± 0.2 11 ± 1.0 12 ± 1.2 
Micrococcus luteus + 14 ± 0.8 10 ± 0.5 0 ± 0 27 ± 1.2 0 ± 0 10 ±0.5 0 ± 0 0 ± 0 13 ± 0.1 0 ± 0 
% of susceptible* bacteria  81.3 78.1 46.9 59.4 18.8 53.1 59.4 56.3 62.5 37.5 
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4.3 Minimum inhibitory concentration (MIC) and Minimum bactericidal concentration (MBC) 
The results of minimum inhibitory concentration (MIC) of the crude extracts against the susceptible 
bacteria are presented in Table 4.3. Extract of NB003 exhibited the MIC in the range of 0.1562 
mg/ml to 5 mg/ml, while NB008 had MIC varying between 0.1562 mg/ml and 2.5 mg/ml. The MIC 
of NB009 extract was revealed to range between 0.039 mg/ml and 1.25 mg/ml and that of NB012 
ranged from 0.1562 mg/ml to 1.25 mg/ml. For NB017, NB022, NB046, NB063 and NB078, and 
NB084 the MICs ranged between 0.039 mg/ml and 10 mg/ml. The MBCs of the extracts ranged 
between 0.625 and >10 mg/ml, with most of the extracts having MBCs of >10 mg/ml (Table 4.4). 
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Table 4.3: Minimum inhibitory concentrations (MICs) of the crude extracts 
Test bacteria Gram 
reaction 
MIC (mg/ml) 
NB003 NB008 NB009 NB012 NB017 NB022 NB046 NB063 NB078 NB084 
Escherichia  coli   ATCC 8739               - 0.625 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Escherichia  coli ATCC 25922                  - 2.5 0.156 0.1562 0.625 1.25 0.625 N/A 0.625 N/A N/A 
Pseudomonas aeruginosa ATCC 19582     - 2.5 1.25 N/A N/A N/A N/A 0.625 0.1562 N/A N/A 
Staphylococcus aureus  ATCC6538           + 2.5 N/A N/A 0.3125 N/A 0.625 1.25 0.1562 N/A 1.25 
Streptococcus faecalis  ATCC 29212       + N/A 0.625 N/A 1.25 N/A N/A 0.625 ND N/A 0.3125 
Bacillus cereus ATCC 10702             + 2.5 0.625 0.078 0.3125 1.25 0.625 0.078 N/A 0.078 0.3125 
Bacillus pumilus ATCC 14884              + 1.25 0.625 0.625 0.625 N/A 0.3125 1.25 0.3125 0.625 1.25 
Pseudomonas aeruginosa ATCC 7700   - 2.5 2.5 N/A N/A N/A N/A 0.625 0.3125 N/A N/A 
Enterobacter cloacae ATCC 13047       - 5 2.5 N/A 1.25 N/A 0.3125 N/A 0.625 1.25 N/A 
Klebsiella pneumonia   ATCC 10031       - 0.3125 2.5 0.3125 0.3125 2.5 0.625 N/A 0.1562 0.625 0.3125 
Klebsiella pneumonia   ATCC 4352        - 0.625 2.5 0.1562 0.3125 2.5 0.625 0.3125 N/A 0.3125 0.3125 
Proteus vulgaris ATCC 6830                 - 2.5 1.25 0.625 0.625 N/A N/A 1.25 N/A 0.078 N/A 
Proteus vulgaris CSIR 0030                  - N/A 2.5 N/A N/A N/A N/A 0.625 0.078 0.3125 N/A 
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Serratia marscens ATCC 9986                - 0.625 1.25 N/A N/A N/A N/A 0.625 0.078 0.625 N/A 
Acinetobacter calcaoceuticus  UP            + 0.625 1.25 0.625 0.1562 N/A 2.5 0.625 N/A 0.078 0.625 
Acinetobactercalcaoceuticus subsp anitratus  
CSIR                                        
+ 0.625 0.3125 N/A 0.3125 N/A N/A 0.039 0.3125 0.3125 0.1562 
Klebsiella pneumonia   KZN              - 5 N/A N/A N/A N/A N/A 0.625 0.3125 
 
0.625 N/A 
Bacillus subtilis  KZN                        + 1.25 0.625 1.25 0.625 N/A 1.25 N/A 0.1562 0.1562 N/A 
Shigella flexineri   KZN                    - N/A N/A 0.625 1.25 N/A N/A N/A N/A N/A N/A 
Salmonella sp KZN                      - 0.1562 0.078 N/A N/A N/A N/A 1.25 N/A 10 N/A 
Staphylococcus epidermides  KZN    - 1.25 N/A N/A 0.625 N/A 5 N/A ND N/A N/A 
Pseudomonas aeruginosa KZN        - N/A 1.25 0.3125 2.5 N/A N/A N/A 0.3125 5 N/A 
Proteus vulgaris  KZN                      - 0.3125 1.25 0.625 N/A N/A N/A N/A N/A 0.3125 N/A 
Enterococcus faecalis  KZN            - N/A N/A 0.078 N/A N/A N/A N/A N/A N/A 2.5 
Escherichia  coli  KZN                  - 2.5 1.25 N/A N/A N/A N/A N/A N/A N/A N/A 
Staphylococcus aureus  KZN           + 0.3125 2.5 N/A 0.3125 N/A 1.25 0.625 N/A 1.25 N/A 
Staphylococcus aureus  OKOH1               + 5 1.25 N/A N/A ND 2.5 N/A N/A ND 0.625 
Staphylococcus aureus  OKOH 2A           + N/A N/A N/A 0.3125 N/A 5 1.25 0.625 N/A N/A 
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Legend: ND- not determined; N/A – Not applicable. 
 
 
 
 
 
 
 
 
 
 
Staphylococcus sciuri   OKOH 2B           + 1.25 0.039 1.25 N/A N/A 0.625 0.3125 N/A N/A N/A 
Staphylococcus aureus  OKOH 3             + 2.5 0.3125 1.25 0.3125 1.25 0.3125 0.039 N/A 0.625 0.625 
Micrococcus kristinae                            + 0.3125 0.625 0.039 0.625 N/A 1.25 
 
0.3125 ND 0.3125 0.625 
Micrococcus luteus                          + 0.1562 0.625 N/A N/A N/A 0.3125 N/A N/A 0.625 N/A 
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Table 4.4: Minimum bactericidal concentrations (MBCs) of the crude extracts 
Test bacteria Gram 
reaction 
MBC (mg/ml) 
NB003 NB008 NB009 NB012 NB017 NB022 NB046 NB063 NB078 NB084 
Escherichia  coli   ATCC 8739 - >10 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Escherichia  coli ATCC 25922 - >10 >10 >10 >10 >10 >10 N/A >10 N/A N/A 
Pseudomonas aeruginosa ATCC 19582 - 10 10 N/A N/A N/A N/A 5 2.5 N/A N/A 
Staphylococcus aureus  ATCC6538 + 10 N/A N/A 0.625 N/A 10 5 N/A N/A >10 
Streptococcus faecalis  ATCC 29212 + N/A 10 N/A >10 N/A N/A 2.5 ND N/A >10 
Bacillus cereus ATCC 10702 + >10 >10 >10 >10 >10 >10 >10 >10 >10 >10 
Bacillus pumilus ATCC 14884 + >10 >10 >10 >10 N/A >10 >10 >10 >10 >10 
Pseudomonas aeruginosa ATCC 7700 - 10 5 N/A N/A N/A N/A 2.5 1.25 N/A N/A 
Enterobacter cloacae ATCC 13047 - >10 >10 N/A >10 N/A >10 N/A >10 >10 N/A 
Klebsiella pneumonia   ATCC 10031 - >10 >10 >10 >10 >10 >10 N/A >10 >10 >10 
Klebsiella pneumonia   ATCC 4352 - >10 >10 >10 >10 >10 >10 >10 N/A >10 >10 
Proteus vulgaris ATCC 6830 - >10 >10 >10 >10 N/A N/A >10 N/A >10 N/A 
Proteus vulgaris CSIR 0030 - N/A >10 N/A N/A N/A N/A >10 >10 2.5 N/A 
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Serratia marscens ATCC 9986 - >10 10 N/A N/A N/A N/A 5 5 >10 >10 
Acinetobacter calcaoceuticus  UP + 5 10 5 >10 N/A 5 2.5 N/A >10 2.5 
Acinetobactercalcaoceuticus subsp anitratus  
CSIR 
+ 5 2.5 N/A 10 N/A N/A 2.5 >10 >10 1.25 
Klebsiella pneumonia   KZN - 10 N/A N/A N/A N/A N/A 1.25 2.5 2.5 N/A 
Bacillus subtilis  KZN + 10 >10 2.5 >10 N/A >10 
 
N/A >10 >10 N/A 
Shigella flexineri   KZN - N/A N/A 2.5 2.5 N/A N/A N/A N/A N/A N/A 
Salmonella sp KZN - 10 5 N/A N/A N/A N/A 5 N/A >10 N/A 
Staphylococcus  epidermides   KZN - 10 N/A N/A >10 N/A >10 N/A ND 0 N/A 
Pseudomonas aeruginosa KZN - N/A 2.5 5 5 N/A N/A N/A 1.25 >10 N/A 
Proteus vulgaris  KZN - 10 2.5 2.5 N/A N/A N/A N/A N/A 10 N/A 
Enterococcus Faecalis  KZN  - N/A N/A 5 N/A N/A N/A N/A N/A N/A N/A 
Escherichia  coli  KZN - 10 2.5 N/A N/A N/A N/A N/A N/A N/A N/A 
Staphylococcus aureus  KZN + 10 5 N/A 5 N/A 5 2.5 N/A >10 N/A 
Staphylococcus aureus  OKOH1 + 10 2.5 N/A N/A ND 10 N/A N/A ND >10 
Staphylococcus aureus  OKOH 2A + N/A N/A N/A 5 N/A >10 2.5 2.5 N/A N/A 
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Legend: ND- not determined; N/A – Not applicable.  
 
 
 
 
Staphylococcus  sciuri   OKOH 2B + 5 2.5 5 N/A N/A 5 2.5 N/A N/A N/A 
Staphylococcus aureus  OKOH 3 + 5 2.5 2.5 10 >10 >10 5 N/A 5 10 
Micrococcus kristinae + 1.25 2.5 2.5 2.5 N/A 10 1.25 ND 2.5 >10 
Micrococcus luteus + 2.5 2.5 N/A N/A N/A 5 
 
N/A N/A 10 N/A 
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4.4 Time kill assay   
The time-kill profile of the crude extracts of the test actinomycetes are as shown in Table 4.5. All 
extracts exhibited both varying degrees of bactericidal and bacteristatic activities depending on the 
test bacteria. A significant decrease in mean viable count of isolates was observed at each time 
interval. Results are presented as Log10 cfu/ml change in the viable colony number. Mean Log 
reduction in viable cell count for NB003 range between 2.18 Log10, 2.84 Log10, 2.61 Log10 and 3.09 
Log10 cfu/ml after 3 hr interaction and between 2.36 Log10, 2.56 Log10, 2.80 Log10 and 3.15 Log10 
cfu/ml after 6 hr interaction in MIC, 2 × MIC, 3 × MIC and 4 × MIC respectively. For NB008 Log 
reduction in viable cell count varied from 1.7 Log10, 2.48 Log10, 2.67 Log10 and 3.05 Log10 cfu/ml 
after 3 hr of interaction at MIC, 2 × MIC, 3 × MIC and 4 × MIC respectively while at 6 hr interaction 
it was revealed as 0.62 Log10, 2.53 Log10, 2.69 Log10 and 3.15 Log10 at MIC, 2 × MIC, 3 × MIC and 
4 × MIC respectively. For NB009, NB012, NB022, NB046, NB063, NB078  and NB084 extracts, 
the Log reduction in viable cell densities ranged between -0.51 Log10 and 4.86 Log10. The utmost 
reductions in cell densities were achieved by NB063, NB022 and NB046 for Staphylococcus aureus 
OKOH 2A (clinical isolate), Micrococcus luteus and Salmonella sp. KZN (environmental isolates) 
with the average reduction in viable cell of 4.86 Log10, 4.38 Log10 and 3.74 Log10 respectively. 
 
4.5 Characterization of crude extract 
The Infrared (IR) spectral of the crude ethyl acetate extracts of putative Streptomyces isolates are 
presented in Appendix A to J. The presence of some functional group as revealed by IR spectral is 
presented in Table 4.6.  
 
4.5.1 Infrared (IR) analysis 
The FTIR Spectral of extracts NB003, NB008, NB009, NB012, NB046, NB063, NB078 and NB084 
show certain common absorption bands between 1700 and 1730 cm
-1 
characteristics of a C=O 
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stretching vibration of a carboxylate functional group. The peaks between 3390 and 3420 cm
-1 
are 
characteristics of hydroxyl υ (O­H) and υ (N­H) vibrational frequency which are interchangeable. A 
common 2 bands Vibrational peak between 2855 and 2979 cm
-1 
are characteristic of a υ (C­H) 
symmetrical vibration of saturated hydrocarbon. 
 The Vibrational frequency υ (C-O) was observed in the spectra of all the extracts around 
1100cm
-1
. Deviation from this region to a higher wave number was observed in the spectra of 
NB008, NB012 and NB084 which could be ascribed to a υ(C-N) vibrational stretch of amide. 
Corresponding N-H symmetrical vibration was observed around 3418 cm
-1
 in the extracts of these 
three isolates indicative of a secondary amide. These peaks were sharper than the υ (O-H) peaks due 
to reduction in hydrogen bonds which increases with electro negativity. 
 In extract NB084, the absence of vibrational peaks between 1600 cm
-1 
and 1640 cm
-1 
gave 
indicates for the absence of unsaturation. Vibrational peaks between 1620 cm
-1 
and 1680 cm
-1 
in 
extract NB022 and NB078 signify possibility of an aromatic compound. Based on the physical state 
(oily) of the extracts and the characteristic features of the infra-red Vibrational peaks in the spectra, 
terpenoids, long chain fatty acids and secondary amine derivatives are possible compounds in the 
extracts. 
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Table 4.5: Antibacterial Time-kill profile of the crude extracts of the fermentation products 
Extracts  
Test bacteria 
MIC 
(Log10 kill) 
2 × MIC 
(Log10 kill) 
3 × MIC 
(Log10 kill) 
4  ×  MIC 
(Log10 kill) 
3 hr 6 hr 3 hr 6 hr 3 hr 6 hr 3 hr 6 hr 
 
NB003 
Proteus vulgaris  KZN 2.18 2.36 2.48 2.56 2.61 2.80 3.09 3.15 
Staphylococcus sciriu  OKOH 2B 1.76 1.06 1.97 1.43 2.16 2.57 2.55 2.80 
Klebsiella pneumonia ATCC 4352 1.10 -0.97 1.25 -0.12 1.38 1.92 1.41 2.24 
 
NB008 
Escherichia  coli ATCC 25922 1.38 -1.0 2.01 0.36 2.65 2.65 3.04 3.08 
Salmonella sp. KZN 1.55 -0.89 1.16 1.14 1.65 1.97 1.78 2.63 
Streptococcus faecalis ATCC 29212 1.70 0.62 2.48 2.53 2.67 2.69 3.05 3.15 
 Staphylococcus sciriu  OKOH 2B 2.64 0.19 2.71 0.72 3.42 1.06 3.58 1.37 
NB009 Bacillus cereus ATCC 10702 1.39 -2.81 1.47 -0.74 3.01 1.27 3.46 2.64 
 Pseudomonas aeruginosa KZN 1.73 1.20 2.26 2.04 2.38 2.11 2.58 2.58 
 Staphylococcus aureus  ATCC6538 2.03 2.11 2.05 2.17 2.18 2.25 2.50 3.39 
NB012 Klebsiella pneumonia  ATCC 10031 1.39 1.87 1.39 2.18 1.56 2.36 1.59 2.39 
 Bacillus pumilus ATCC 14884 1.52 2.10 1.97 2.39 2.40 3.04 3.69 3.79 
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NB022 Staphylococcus aureus  ATCC 6538  1.52 2.10 1.97 2.39 2.40 3.06 3.69 3.79 
 Micrococcus luteus 1.5 1.49 1.72 1.72 3.44 2.55 3.99 4.38 
NB046 Streptococcus faecalis  ATCC 29212 1.53 -0.83 1.53 0 2.19 0.26 2.31 0.60 
 Salmonella sp.  KZN 1.14 -2.4 1.50 0.55 2.59 2.70 3.07 3.74 
NB063 Staphylococcus aureus  OKOH 2A 1.44 1.26 1.65 2.14 1.81 2.47 3.92 4.86 
 Pseudomonas aeruginosa ATCC 19582 2.71 2.63 3.01 3.03 3.04 3.21 3.59 3.78 
 Serratia marscens ATCC 9986 1.32 -1.51 2.59 -0.51 2.63 -0.35 2.75 -0.22 
 Klebsiella pneumonia   ATCC 4352 1.39 -0.81 1.73 0.19 2.42 1.97 2.72 2.8 
NB078 Proteus vulgaris CSIR 0030 0.86 -2.16 1.10 -0.89 1.30 -0.79 1.30 0.01 
 Staphylococcus aureus  OKOH 3 2.10 -2.10 2.67 -1.83 3.02 1.47 3.04 1.01 
NB084 Streptococcus faecalis  ATCC 29212 1.26 -1.32 2.30 0.183 2.34 2.61 3.41 3.45 
 Acinetobacter calcaoceuticus subsp anitratus  
CSIR 
2.35 0.51 2.49 0.63 2.71 1.05 3.25 1.27 
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Table 4.6: IR spectral of functional groups present in crude ethyl acetate extracts of putative 
Streptomyces isolate 
Extracts υ (N­H) 
(cm
-1
) 
υ  (C=O) 
(cm
-1
) 
υ(C­O) 
(cm
-1
) 
υ (O­H) 
(cm
-1
) 
υ (C-N) 
(cm
-1
) 
υ (C=C) 
(cm
-1
) 
υ (C­H) 
(cm
-1
) 
NB003  1709, 
1665 
1090, 1016 3392   2975 
NB008 3415 1702   1270  2961 
NB009  1712 1121  3411  2902 
NB012 3420 1724 1052   1638 2924 
NB017   1100 3435  1648 2959 
NB022  1726  3417  1662 2926 
NB046  1664 1077 3400   2962 
NB063  1712 1091 3392   2975 
NB078  1709 1091 3397  1655 2979 
NB084 3415 1709   1217  2964 
 
 Legend: υ(N­H) Vibrational frequency of Nitrogen-Hydrogen bond; υ(C=O) Vibrational frequency 
of Carbon oxygen double bond; υ(C-O) Vibrational frequency of Carbon oxygen single bond; υ(O-H) 
Vibrational frequency of hydroxyl group; υ(C-N) Vibrational frequency of carbon nitrogen bond; 
υ(C=C) Vibrational frequency of carbon- carbon unsaturated bond; υ(C-H) Vibrational frequency of 
saturated Carbon hydrogen bond, (sp
3
 hybridised). 
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CHAPTER FIVE 
 
DISCUSSION AND CONCLUSION 
5.1 Discussion  
The incidence of multi drug resistant organisms is increasing and is a problem of global concern. 
Despite the broad range of activities, the most studied bioactive metabolites through history has been 
the antibiotics. Currently, appearance of multiple antibiotic resistances in pathogenic bacteria is 
increasing, compromising the clinical treatment of a growing number of infectious diseases. There is 
thus an urgent need for new drugs effective against current antibiotic resistant pathogens and 
opportunistic pathogens. Interestingly marine actinomycetes produce many potential pharmacological 
compounds with antibiotic and antitumor properties Suthindhiran and Kannabira, 2009. Streptomyces 
have been proven as a potential source of bioactive compounds and richest source of secondary 
metabolites (Suthindhiran and Kannabira, 2009). The search for active secondary metabolites 
produced by environmental isolates, using poorly explored microorganisms, could provide a new 
source for discovering novel bioactive compounds.   
Significant attention is currently being paid to the isolation and characterization of 
Streptomyces from poorly researched habitats given the premise that screening such organisms raises 
the prospect of discovering new natural products that can be developed as a resource for 
biotechnology (Bredholt et al., 2008; Eccleston et al., 2008). This reasoning appears to be sound as 
novel Streptomyces isolated from unexplored marine habitats are proving to be a valuable source of 
new bioactive metabolites (Bull and Stach, 2007; Fiedler et al., 2005). It seems timely, therefore, to 
extend this approach to another poorly studied environment, such as the Nahoon beach ecosystem.  
It was not intended in the present investigation to assemble a detailed record of the kinds of 
Streptomyces found in the Nahoon beach environment or to isolate and characterize novel bioactive 
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compounds, but the study was designed to prepare the ground for such studies by isolating, partially 
characterizing and screening a diverse range of Streptomyces.  
Many of the strains evaluated in the present study showed bioactivity against one or more of 
the screening systems, thereby underpinning and extending results from previous studies which 
showed Nahoon beach to be a source of bioactive Streptomyces. It is becoming increasingly evident 
that the taxonomic and metabolic diversity encompassed by Streptomycetes is remarkable, as new and 
putatively novel Streptomyces species are being continuously isolated from under-researched habitats 
and shown to be valuable sources of new bioactive compounds. 
The antimicrobial activities of the extracts were tested against a wide range of 
microorganisms (Table 4.2). These extracts showed activities against a minimum of 6 test bacteria 
and maximum of 26 among the 32 test bacteria amounting to approximately 18.8 to 81.3 % 
antibacterial activities (Table 4.2). This percentage is higher than those described by Barakate et al. 
(2002) studying the activity of Moroccan soil Streptomyces. These results were also different from 
those of other authors showing 16% in soil of Turkey (Oskay et al., 2004); 53 – 61% in Algerian soil 
(Sabaou et al., 1998) and 44.5% in soils of South-Eastern Serbia (Illic et al., 2005; 2007). On the 
other hand, similar inhibition pattern was demonstrated by the ethyl acetate extracts of marine 
Streptomyces RM17 and RM42 (Remya and Vijayakumar, 2008); marine Streptomyces isolates from 
the Andaman Coast of the Bay of Bengal (Peela et al., 2005); and marine Streptomyces strain Merv 
1996 and Merv 7409 (El-Gendy et al., 2008b); although more bacteria species were screened in this 
study. The antibacterial spectrum exhibited by all extracts highlights their potentials and suggests that 
they could be important candidates for antibiotics in this regard. Further studies on the bioactive 
metabolites produced by these extracts which exhibits broad spectrum activity is under progress. 
Overall the study gives the first hand information on the antimicrobial activity of putative indigenous 
Streptomyces isolated from the Nahoon beach environment. 
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The differences in the susceptibilities of Gram positive and Gram negative bacteria to the 
study Streptomyces extracts have been observed by previous workers (Ilic et al., 2007). Gram 
negative bacteria are inherently more resistant to antimicrobials than Gram positive organisms and 
this has been ascribed to the combined exclusion of antimicrobial compounds by double membrane 
barrier and transmembrance efflux present in this group of organisms (Zgurskaya and Nikaido, 2000).   
The biological activities (MIC and MBC) of the crude extracts emphasizes that the extracts 
are active against Gram-positive and Gram-negative bacteria. The MICs values exhibited by all 
extracts in this study ranged between 0.039 mg/ml and 10 mg/ml. This was relatively higher than the 
MIC values obtained from marine Streptomyces strain Merv 1996 (El-Gendy et al., 2008b) against B. 
subtilis ATCC 6051, S. aureus ATCC 6538 and M. luteus with MICs of 0.0036 mg/ml, 0.0008 mg/ml 
and 0.002 mg/ml respectively; Streptomyces sp. AZ-NIOFD1 isolated from River Nile water, Egypt 
(Atta et al., 2009) with MIC range of 0.0117 mg/ml - 0.03125 mg/ml; and marine Streptomyces sp.  
Merv 8102 (El-Gendy et al., 2008a). However, Pandey et al. (2004) mentioned that the MIC is not a 
constant for a given agent, since it is influenced by a number of factors. These factors include the 
nature of the test organism used, the inoculum size, and the composition of the culture medium, the 
incubation time, and aeration.  
In general, some extracts of these putative Streptomyces had antibacterial activities against 
Gram positive bacteria, especially staphylococci. Staphylococci are among the most commonly 
encountered pathogens in clinical practice. S. aureus is a major cause of nosocomial infections, food 
poisoning, osteomyelitis, pyoarthritis, endocarditis, toxic shock syndrome, and a broad spectrum of 
other disorders (Todd, 1998; Hajjeh et al., 1999; Rubin et al., 1999). In recent years, there has been 
an alarming increase in nosocomial staphylococcal infections by strains with multiple drug resistance 
(Al-Masaudi et al., 1991; Kloos and Bannerman, 1995; Hiramatsu et al., 1997). At present, this 
situation is leading to the evaluation of staphylococcal pathogens potentially resistant to any available 
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antibiotic (Noble et al., 1992; Huycke et al., 1998; Rubin et al., 1999). Therefore, the result of this 
study may suggest that the extracts of the species possess compounds with antimicrobial properties 
which can be used as antimicrobial agents in new drugs for therapy of infectious diseases in human. 
Time-kill studies have been used to investigate numerous antimicrobial agents. They are also 
often used as the basis for in vitro investigations into pharmacodynamic drug interactions. They 
provide descriptive (qualitative) information on the pharmacodynamics of antimicrobial agents. They 
are also used to provide clinically relevant assay of the activity of antimicrobial agents. The time kill 
assay of the crude extracts of the test Streptomyces isolates gave variable kinetics among susceptible 
bacteria tested (Table 4.5). Both bactericidal and bacteristatic activities were demonstrated by the 
extracts. The extracts exhibited a partially concentration-dependent killing profile. Although 
literatures on time kill kinetics of marine Streptomyces is scarce, time kill kinetics of a marine 
bacterium against clinical methicillin resistant Staphylococcus aureus (MRSA) isolate has been 
reported by Isnansetyo and Kamei (2003). In their study, bactericidal activity has demonstrated to be 
much higher than vacomycin therefore, time kill studies of these marine Streptomyces proposes their 
possible outcome in in vivo studies.  
Extracts of NB008 was bactericidal with 4 × MIC against Streptococcus faecalis ATCC 
29212 at 3 hr and a slight increase in activity at 6 hr interaction. However, a bacteristatic activity was 
observed at lower concentrations. Watanakunakorn and Tisonel (1982), reported time kill kinetics of 
the combination of N-Formimidoyl' thienamycin (MK0787) a stable derivative of thienamycin, 
derived from Streptomyces cattleya with gentamicin or with tobramycin against enterococci. In their 
study a combination of N-Formimidoyl' thienamycin with gentamicin or with tobramycin showed 
over 95% bactericidal activity against forty-seven strains of Streptococcus faecalis tested. Therefore 
Extracts of NB008 compound or its derivative either single or in combinational therapy with other 
antibiotics suggest potential use against enterococcal infections. NB008 showed bacteristatic action 
against Salmonella sp at all concentrations tested. However, stronger bacteristatic activity was 
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observed with higher concentrations (3 × MIC and 4 × MIC) and longer time. It can be assumed that 
at higher concentration of this extract, aggressive bactericidal activity against Salmonella sp would be 
achieved. 
NB063 exhibited bacteristatic activity with MIC at 3 hr and 6 hr against Pseudomonas 
aeruginosa ATCC 19582. Furthermore, bactericidal activity was demonstrated with 2 × MIC, 3 × 
MIC and 4 × MIC at 3 hr and 6 hr interactions. P. aeruginosa is an important pathogen associated 
with serious nosocomial infections such as pneumonia and sepsis (Tam et al., 2005). It is also 
associated with multiple mechanisms of resistance to various antimicrobial agents (Tam et al., 2005). 
Treatment of pseudomonal infections often presents a challenge to clinicians and combination 
therapy is commonly used to prevent the emergence of resistance (Tam et al., 2005). However, from 
the Time-kill profile among all extracts and susceptible bacteria tested in this study, NB063 showed 
the best time kill profile against Pseudomonas aeruginosa ATCC 19582 in the sense that bactericidal 
activity was observed with 2 × MIC with a stepwise increase in bactericidal activity with 
concentration and time. Although NB009 exhibited a strong bacteristatic activity against an 
environmental strain of Pseudomonas aeruginosa KZN, NB063 is the only extract that demonstrated 
bactericidal activity with 2 × MIC concentration. NB063 proposes to be an important agent against 
pseudomonal infections. 
Anti-pneumococcal activity of two strains of pneumococcal bacteria - Klebsiella pneumonia 
ATCC 10031 and Klebsiella pneumonia ATCC 4352 was demonstrated by NB012 and NB078 
respectively.  Time kill profile of anti-pneumococcal activities of some antibiotics has been reported 
(Pankuch et al., 1996) but the anti-pneumococcal time kill profile of marine Streptomyces is limited, 
this appear to be the first report of anti-pneumococcal time kill profile of extracts of marine 
Streptomyces (Table 4.5). These extract (NB012 and NB078) promises to be important drug 
candidates for the development of anti-pneumococcal antibiotics.  The re-growth phenomenon 
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exhibited by some extracts against certain bacteria could be attributed to instability of the crude 
extracts in the growth medium. 
IR spectra of crude extracts showed some similarities in their content due to presence of some 
functional groups, but the different vibrational peaks of these functional groups in these extracts 
depicts that the extracts were different hence the diverse activity they exhibited against test organisms 
especially during the susceptibility screening and MIC assessment. The IR spectrum of an antifungal 
compound: 4' phenyl -1-napthyl –phenyl acetamide from Streptomyces sp. DPTB16 indicates that the 
compound had NH2 and -OH group (Dhanasekaran et al., 2008). Similar functional group and spectra 
profiles were exhibited by these extracts suggesting similarity with these extracts and this could be 
attributed to antifungal activity demonstrated by some of the extracts during preliminary screening 
(Table 4.1). The distribution of the antibiotic inhibition phenotype of Streptomycetes with great 
antibacterial and antifungal activity which gave a similar spectral profile has also been reported (Illic 
et al., 2007). Nevertheless, further investigation is needed in order to purify and determine the 
structure of the active components in the extracts. 
 
5.2 Conclusion  
The present finding highlights the importance for further investigation towards the goal of obtaining 
novel antimicrobial agent from the putative Streptomyces from this untapped habitat. The Nahoon 
beach habitat appears to be an unexplored area in this environment, with unique ecological niches and 
rich in biodiversity (Unpublished data). The microbiology of the Nahoon beach environment has to 
be further explored in order to get benefit out of the precious biowealth, more so as it has great 
demand from the perspective of health care especially as regards combating existing and emerging 
drug resistant pathogens. The emergence and dissemination of antibacterial resistance is well 
documented as a serious problem worldwide. It is anticipated that due to the antibacterial profile and 
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characterization of the crude extracts, putative marine Streptomyces isolated from Nahoon Beach 
promises to be useful in the discovery of novel  antibiotics. 
It is therefore recommended that further investigation should address the relationship between 
the structure of the active component of the extracts and the broad spectrum activity, as well as a 
rapid method for large scale production and purification and whether this group of antibiotics has any 
application in managing human infectious disease. 
 
5.3 Limitation of the study 
There was limit using Mass spectrum, nuclear magnetic resonance (NMR) spectrum and High 
performance liquid chromatography (HPLC) spectrum to elucidate the possible structure of the 
metabolites (compound) isolated from the Streptomyces strains due to time and resource constrains 
and lack of  elemental analytical instruments in my institution (University of Fort Hare). 
 
5.4 Recommendation 
Based on the findings of this study the following recommendations are suggested: 
 There is need for further studies to optimize the production conditions of the bioactive 
compounds isolated from the marine Streptomyces. 
  In the future elemental analytical instrumentation should be employed in the identification 
and purification of the isolated bioactive compounds; possibly as a doctoral study.  
 There may be need to test the anticancer (cytotoxicity studies), antifungal, antiviral, and anti-
inflammatory activities of the extracted biomolecule in the future. 
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5.5 Potential for future development of the study 
The marine environment is becoming increasingly appreciated as a rich and untapped reservoir of 
novel natural products. Bioactive compounds are frequently associated with marine organism. In the 
current study, Streptomyces strains (marine origin) showed good potentials as source of novel 
secondary metabolites.  Although time-kill kinetics was used to monitor the rate of kill of the 
extracted biomolecules against individual bacteria, there is limited information in the literature on 
imaging of time-kill kinetics at the cellular level. Thus future studies may focus on this area to 
broaden our knowledge and understanding of the mechanisms involved in this process. Information 
from such research may add to our current knowledge of the pathogen-host relationship and will help 
to determine the target site of the cell organelles that these biomolecules attack or have affinity for. 
This could also help to tackle resistance problem.  
The focus of the current study was on the antimicrobial activity of extracted biomolecule from 
Streptomyces against a panel of bacteria; in the future biological activity of the biomolecule could be 
expanded to include other biological assay such as anticancer (cytotoxicity studies), antifungal, 
antiviral, and anti-inflammatory activities. Such investigations could give an excellent perspective to 
the metabolites activity. Other assays that may be considered in future studies include: chemical 
characterization of bioactive metabolites using chromatographic methods (e.g. HPLC) in order to 
isolate pure metabolites. Structural elucidation using mainly one dimensional (1D) or two 
dimensional (2D) NMR techniques. This will greatly enhance the identification of the active 
components in the metabolites (culture extracts). The discovery of novel metabolites in marine 
microorganisms has become more difficult due to the enormous number of known compounds 
already described in the literature.  
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APPENDIX A 
 
IR spectral of crude ethyl acetate extract of isolate NB003 
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APPENDIX B 
 
 IR spectral of crude ethyl acetate extract of isolate NB008 
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APPENDIX C 
 
IR spectral of crude ethyl acetate extract of isolate NB009 
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APPENDIX D 
 
IR spectral of crude ethyl acetate extract of isolate NB012 
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APPENDIX E 
 
IR spectral of crude ethyl acetate extract of isolate NB017 
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APPENDIX F 
 
 IR spectral of crude ethyl acetate extract of isolate NB022 
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APPENDIX G 
 
 IR spectral of crude ethyl acetate extract of isolate NB046 
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APPENDIX H 
 
 IR spectral of crude ethyl acetate extract of isolate NB063 
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APPENDIX I 
 
 IR spectral of crude ethyl acetate extract of isolate NB078 
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APPENDIX J 
 
 IR spectral of crude ethyl acetate extract of isolate NB084 
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